☐
|
| |
Preliminary Proxy Statement
|
☐
|
| |
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
☒
|
| |
Definitive Proxy Statement
|
☐
|
| |
Definitive Additional Materials
|
☐
|
| |
Soliciting Material Pursuant to Section 240.14a-12
|
1.
|
To elect eight directors to have terms expiring in 2022, and until their successors shall be elected and duly qualified;
|
2.
|
To consider and vote upon a proposal to amend our Amended and Restated 2015 Omnibus Incentive Plan to increase the number of shares reserved for issuance thereunder from 11,500,000 to 19,500,000;
|
3.
|
To consider and vote upon an advisory proposal concerning our executive compensation program;
|
4.
|
To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2022; and
|
5.
|
To consider such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
|
Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to be Held on
|
|
|
September 13, 2021
|
|
|
|
|
|
In accordance with rules and regulations adopted by the Securities and Exchange Commission, we are furnishing our proxy materials on the Internet. “Proxy materials” means this proxy statement, our 2021 Annual Report and any amendments or updates to these documents. Our proxy materials are available on the Internet to the general public at http://materials.proxyvote.com/703395.
|
|
|
| |
Page
|
| | ||
| | ||
| | ||
|
| |
|
| | ||
|
| |
|
| | ||
| | ||
| | ||
|
| |
|
| | ||
| | ||
| | ||
|
| |
|
| | ||
|
| |
|
| | ||
|
| |
|
| | ||
|
| |
|
| | ||
|
| |
|
| | ||
|
| |
|
| |
■
|
The election of eight directors to have terms expiring in 2022, and until their successors shall be elected and duly qualified;
|
■
|
Approval of an amendment to our Amended and Restated 2015 Omnibus Incentive Plan to increase the number of shares reserved for issuance thereunder from 11,500,000 to 19,500,000;
|
■
|
Advisory approval of our executive compensation program; and
|
■
|
Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2022.
|
■
|
FOR election of each of the nominees for director (see Proposal No. 1);
|
■
|
FOR approval of the amendment to our Amended and Restated 2015 Omnibus Incentive Plan (See Proposal No. 2);
|
■
|
FOR advisory approval of our executive compensation program (see Proposal No. 3); and
|
■
|
FOR ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending April 30, 2022 (see Proposal No. 4).
|
■
|
If you abstain from voting on a nominee or a proposal, your shares will be considered present at the annual meeting for purposes of determining a quorum and for purposes of calculating the shares present and entitled to vote on the nominee or the proposal and, accordingly, will have the same effect as a vote against the nominee or proposal.
|
■
|
If you do not vote (or a broker non-vote occurs) on a nominee or a proposal, your shares will not be deemed present for the purposes of calculating the vote on that nominee or proposal and will generally have no impact on determining whether the nominee is elected or the proposal is approved.
|
|
Name
|
| |
Age
|
| |
Principal Occupation
|
| |
Position(s) with Patterson
|
| |
Director Since
|
|
|
John D. Buck
|
| |
71
|
| |
Chief Executive Officer of Whitefish Ventures, LLC
|
| |
Chairman of the Board
|
| |
2006
|
|
|
Alex N. Blanco
|
| |
60
|
| |
Former Executive Vice President and Chief Supply Chain Officer of Ecolab Inc.
|
| |
Director
|
| |
2017
|
|
|
Jody H. Feragen
|
| |
65
|
| |
Former Executive Vice President and Chief Financial Officer of Hormel Foods Corporation
|
| |
Director
|
| |
2011
|
|
|
Robert C. Frenzel
|
| |
50
|
| |
President and Chief Operating Officer of Xcel Energy Inc.
|
| |
Director
|
| |
2018
|
|
|
Francis J. Malecha
|
| |
57
|
| |
Manager of Hidden Lake Vineyard, LLC
|
| |
Director
|
| |
2018
|
|
|
Ellen A. Rudnick
|
| |
70
|
| |
Senior Advisor on Entrepreneurship, University of Chicago Booth School of Business
|
| |
Director
|
| |
2003
|
|
|
Neil A. Schrimsher
|
| |
57
|
| |
President and Chief Executive Officer of Applied Industrial Technologies, Inc.
|
| |
Director
|
| |
2014
|
|
|
Mark S. Walchirk
|
| |
55
|
| |
President and Chief Executive Officer of Patterson Companies, Inc.
|
| |
President, Chief Executive Officer, Director
|
| |
2017
|
|
|
Summary of Director Qualifications and Experience
|
| |
John Buck
|
| |
Alex Blanco
|
| |
Jody Feragen
|
| |
Robert Frenzel
|
| |
Francis Malecha
|
| |
Ellen Rudnick
|
| |
Neil Schrimsher
|
| |
Mark Walchirk
|
|
|
Large Company Experience as Executive or Board Member is important because of the complex and unique management requirements for a large, public company.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Extensive Knowledge of Patterson History allows our Board of Directors to learn from our history and what works for our company.
|
| |
X
|
| |
|
| |
X
|
| |
|
| |
|
| |
X
|
| |
X
|
| |
|
|
|
Healthcare Industry Experience facilitates relevant, efficient, and effective discourse relating to our business and strategy.
|
| |
X
|
| |
X
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
X
|
|
|
International Business Experience is important because of our global reach and the growing interconnectivity of people and industry.
|
| |
X
|
| |
X
|
| |
|
| |
|
| |
X
|
| |
X
|
| |
X
|
| |
|
|
|
Financial Literacy is necessary to understand our financial reports, internal controls, and the complex transactions we conduct regularly.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Public Company Governance Experience assists directors with diligent management of accountability, transparency and protection of shareholder interests.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Experience in Marketing and Sales is crucial in understanding how to most effectively sell our products in existing markets and to expand to new ones.
|
| |
|
| |
X
|
| |
|
| |
|
| |
|
| |
|
| |
X
|
| |
X
|
|
|
Operations Experience helps in understanding the balance between efficiency and the highest level of quality controls.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
|
| |
X
|
| |
X
|
|
|
Experience in Human Resources, Culture and Compensation allows directors to help us hire, motivate, and retain the best employees.
|
| |
X
|
| |
X
|
| |
|
| |
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Understanding and Previous Work with Technology Solutions will allow our company to innovate and thrive in a world that relies more heavily than ever on interconnectivity of systems and tech.
|
| |
|
| |
X
|
| |
|
| |
|
| |
|
| |
|
| |
X
|
| |
X
|
|
|
Experience in Capital Allocation and Deployment allows directors to decide on the proper placement of assets and funds, manage risks, and invest smartly in upcoming and lucrative avenues.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Business Development Experience (including M&A) is important because of the board’s role in strategic planning of mergers, acquisitions, and divestitures.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
|
Regulatory Experience allows our directors to provide oversight of our regulated activities and risk management.
|
| |
X
|
| |
X
|
| |
|
| |
X
|
| |
X
|
| |
X
|
| |
|
| |
X
|
|
|
Enterprise Risk Management, including business continuity and cyber security, allows our company to thrive in a rapid-paced market.
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
| |
X
|
|
■
|
The role of our Board of Directors,
|
■
|
The composition of our Board and selection of directors,
|
■
|
Functioning of our Board and its committees,
|
■
|
Compensation of directors, and
|
■
|
Conduct and ethics standards for directors.
|
■
|
Supporting the efforts of Paterson UNITES, a volunteer group of Patterson team members focused on building and executing our diversity and inclusion strategy, including among other things the UNITES LGBTQA+ Affinity Group;
|
■
|
Developing and executing a mentorship initiative designed to advance the growth and development of women throughout the organization through participation in peer-mentoring circles as well as one-on-one mentoring;
|
■
|
Partnering with WILMAH, Women in Leadership and Management in Animal Health, an organization that mirrors our dedication to the well-being of all animals and provides opportunities to help women achieve success at every stage of their careers;
|
■
|
Supporting the Patterson Foundation scholarship program, which provides annual renewable scholarships to dependents of Patterson employees, and continued donations to dental and animal health nonprofit organizations;
|
■
|
Improving and promoting environmental health and safety initiatives;
|
■
|
Focusing on sustainability efforts at our corporate headquarters, in our fleet program, and through operational management by reducing waste, minimizing our carbon footprint, recycling materials, and managing shipping efficiencies; and
|
■
|
Delegating for the first time oversight of our environmental, social and governance efforts to our Governance and Nominating Committee.
|
■
|
Calling meetings of the Board and meetings of our independent directors;
|
■
|
Presiding over Board meetings, including executive sessions of our independent directors;
|
■
|
Briefing the Chief Executive Officer on issues and concerns arising in the executive sessions of the Board;
|
■
|
Being available, when requested and appropriate, for consultation and direct communication with shareholders;
|
■
|
Reviewing and approving all information sent to our Board, including the quality, quantity, appropriateness and timeliness of such information;
|
■
|
Establishing meeting agendas for our Board in consultation with members of senior management;
|
■
|
Reviewing and approving the scheduling of Board meetings, assuring there is sufficient time for discussion of all agenda items;
|
■
|
Coordinating Board input and review of management’s strategic plan for the company;
|
■
|
Working with the Governance and Nominating Committee with respect to the recruitment, selection and orientation of new Board members as well as committee composition;
|
■
|
Overseeing the Compensation Committee’s development of appropriate objectives for the Chief Executive Officer and monitoring performance against those objectives;
|
■
|
Coordinating and chairing the annual Board performance review of the Chief Executive Officer and communicating results to the Chief Executive Officer;
|
■
|
Leading the Board’s review of the succession plan for the Chief Executive Officer and other executive officers;
|
■
|
Coordinating the Board’s self-assessment and evaluation processes;
|
■
|
Serving as a member of Governance and Nominating Committee and such other committees as assigned by the Board; and
|
■
|
Reviewing, on an annual basis and in consultation with our independent directors, this list of responsibilities and recommending to our Board for approval any modifications or changes.
|
|
Name
|
| |
Audit
|
| |
Compensation
|
| |
Governance
and
Nominating
|
| |
Compliance
|
| |
Independent
Director
|
|
|
John D. Buck
|
| |
|
| |
|
| |
X*
|
| |
X
|
| |
X
|
|
|
Alex N. Blanco
|
| |
|
| |
X
|
| |
|
| |
X
|
| |
X
|
|
|
Jody H. Feragen
|
| |
X
|
| |
|
| |
|
| |
X
|
| |
X
|
|
|
Robert C. Frenzel
|
| |
X*
|
| |
|
| |
X
|
| |
|
| |
X
|
|
|
Francis J. Malecha
|
| |
X
|
| |
X
|
| |
|
| |
|
| |
X
|
|
|
Ellen A. Rudnick
|
| |
|
| |
X*
|
| |
X
|
| |
|
| |
X
|
|
|
Neil A. Schrimsher
|
| |
|
| |
X
|
| |
X
|
| |
X*
|
| |
X
|
|
|
Mark S. Walchirk
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
*
|
Denotes committee chairperson.
|
■
|
Evaluate annually our Chief Executive Officer’s and other executive officers’ compensation levels and payouts;
|
■
|
Determine for our executive officers, and recommend to our Board for approval with respect to the Chief Executive Officer, all components of compensation, including annual base salary levels, annual incentive opportunity levels, long-term incentive opportunity levels, executive perquisites, employment agreements, change-in-control provisions or agreements, severance agreements, benefits, supplemental benefits and any special financial compensation programs;
|
■
|
Review and recommend to our Board for approval any equity compensation program involving the use of our company’s securities, including stock options and restricted stock;
|
■
|
When appropriate, select, retain and terminate independent compensation consultants, independent legal counsel or other advisors to advise the committee;
|
■
|
Ensure that the compensation for our Chief Executive Officer and other executive officers is consistent with our company’s executive compensation policy;
|
■
|
Advise and assist our company in defining its total compensation policy;
|
■
|
Review and comment on the compensation program to ensure that it supports our company’s strategic and financial plans;
|
■
|
Review and recommend to our Board for approval new incentive plans that are consistent with the total compensation policy, and monitor the appropriateness of payouts under alternative business scenarios;
|
■
|
Review retirement plans to ensure they meet company objectives and are in compliance with relevant laws and regulations;
|
■
|
Review the establishment, amendment and termination of employee benefits plans, including equity plans, and oversee the operation and administration of such plans;
|
■
|
Review our company’s compensation policies for regulatory and tax compliance, including structuring compensation programs to preserve tax deductibility and, as required and to the extent applicable under relevant transition relief rules, establishing performance goals and certifying that performance goals have been attained;
|
■
|
Considering the results of the most recent shareholder advisory vote on executive compensation in making determinations and recommendations regarding our company’s executive compensation policy and decisions;
|
■
|
Prepare a report on executive compensation in our company’s proxy statement as required by Securities and Exchange Commission rules;
|
■
|
Review annually our company’s risk assessment to determine whether compensation policies and practices are reasonably likely to have a material adverse effect on our company;
|
■
|
Review and discuss with management the “Compensation Discussion and Analysis” required by Securities and Exchange Commission Regulation S-K, Item 402, and determine whether to recommend to our Board that the “Compensation Discussion and Analysis” be included in our company’s annual proxy statement for the annual meeting of shareholders;
|
■
|
Review and modify, as appropriate, stock ownership guidelines applicable to executive officers and non-employee directors, and oversee the application of such guidelines; and
|
■
|
Fulfill such other duties and responsibilities as may be assigned to the committee by our Board or Chairman of the Board.
|
■
|
The name of the person recommended as a director candidate;
|
■
|
All information relating to such person that is required to be disclosed in solicitations of proxies for election of directors pursuant to Exchange Act Regulation 14A;
|
■
|
The written consent of the person being recommended as a director candidate to being named in the proxy statement as a nominee and to serving as a director if elected;
|
■
|
As to the shareholder making the recommendation, the name and address, as they appear on the books of Patterson Companies, Inc., of such shareholder; provided, however, that if the shareholder is not a registered holder of common stock, the shareholder must submit his or her name and address along with a current written statement from the record holder of the shares that reflects ownership of our common stock; and
|
■
|
A statement disclosing whether such shareholder is acting with or on behalf of any other person and, if applicable, the identity of such person.
|
■
|
Provide oversight and monitoring of compliance matters, provided that the Audit Committee has sole oversight over compliance programs relating to financial matters, including auditing, financial reporting and disclosures to investors;
|
■
|
Provide oversight and monitoring of our company’s Compliance Program and receive periodic reports from management regarding the same;
|
■
|
Monitor our company’s efforts to implement programs, policies and procedures relating to compliance matters, and the training of employees and others on such matters;
|
■
|
Review the results of compliance-related audits conducted by our company and by regulators, such as the DEA and FDA;
|
■
|
Request or oversee the investigation of any significant instances or potential instances of noncompliance with laws or our company’s Compliance Program, polices or procedures; provided, however, that any instances or potential instances of financial noncompliance are to be directed to the Audit Committee for investigation;
|
■
|
Review any violations of our company’s Code of Conduct by any executive officer or director, and review, assess and/or recommend corrective action;
|
■
|
If there is a government or regulatory action that, in the judgment of the committee, has caused significant financial or reputational damage to our company or otherwise indicates a significant compliance or regulatory issue within our company, then the committee shall make a written recommendation to the Compensation Committee concerning the extent, if any, to which the incentive-based compensation of any executive officer involved in the conduct at issue or with direct supervision over an employee that engaged in the conduct at issue should be reduced, extinguished, or recouped;
|
■
|
Review on a regular basis litigation matters filed against our company related to alleged violations of laws and regulations;
|
■
|
Review on a regular basis our company’s compliance risk assessment plan;
|
■
|
Identify and investigate emerging compliance issues and trends which may affect our company;
|
■
|
Periodically review our company’s compliance oversight structure and allocation of resources and responsibilities across the organization;
|
■
|
Conduct an annual evaluation of the performance and effectiveness of the Compliance Committee and report the results of that evaluation to the Board;
|
■
|
Report to the Audit Committee on compliance matters reviewed by the Compliance Committee that may impact our company’s financial statements and our accounting and financial reporting processes;
|
■
|
At least annually, coordinate with the Audit Committee to discuss matters of mutual interest within the context of each committee’s respective areas of oversight; and
|
■
|
Have such other duties and oversight and monitoring responsibilities as may be assigned from time to time by the Board and/or the Chairman of the Board.
|
■
|
Maintained annual cash retainer of $90,000;
|
■
|
Increased all committee chair retainers to $25,000;
|
■
|
Increased all committee member retainers to $10,000;
|
■
|
Increased the annual equity retainer to $145,000; and
|
■
|
Maintained the annual cash retainer of $100,000 for the non-executive Chairman of the Board.
|
|
Name
|
| |
Fees
Earned
or
Paid in
Cash
($)
|
| |
Stock
Awards
($) (a)
|
| |
Option
Awards
($) (b)
|
| |
Non-Equity
Incentive Plan
Compensation
($)
|
| |
Change in Pension
Value and
Nonqualified
Deferred
Compensation
Earnings
($)
|
| |
All Other
Compensation
($)
|
| |
Total
($)
|
|
|
John D. Buck
|
| |
196,875
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
312,876
|
|
|
Alex N. Blanco
|
| |
107,813
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
223,814
|
|
|
Jody H. Feragen
|
| |
121,875
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
237,876
|
|
|
Robert C. Frenzel
|
| |
117,188
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
233,189
|
|
|
Francis J. Malecha
|
| |
103,125
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
219,126
|
|
|
Ellen A. Rudnick
|
| |
107,813
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
223,814
|
|
|
Neil A. Schrimsher
|
| |
117,188
|
| |
116,001
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
233,189
|
|
(a)
|
Represents the aggregate grant date fair value of the 4,704 shares of restricted stock awarded to each non-employee director on September 14, 2020, the date of our 2020 annual meeting of shareholders, computed in accordance with FASB ASC Topic 718. Information on the assumptions used to calculate such value is set forth in Note 15 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended April 24, 2021. The aggregate number of unvested shares of restricted stock outstanding at fiscal year-end 2021 held by our non-employee directors was as follows:
|
|
Name
|
| |
Number of
Shares of
Restricted Stock
|
|
|
John D. Buck
|
| |
4,704
|
|
|
Alex N. Blanco
|
| |
4,704
|
|
|
Jody H. Feragen
|
| |
4,704
|
|
|
Robert C. Frenzel
|
| |
4,704
|
|
|
Francis J. Malecha
|
| |
4,704
|
|
|
Ellen A. Rudnick
|
| |
4,704
|
|
|
Neil A. Schrimsher
|
| |
4,704
|
|
|
Total
|
| |
32,928
|
|
(b)
|
The aggregate number of unexercised stock options outstanding at fiscal year-end 2021 held by our non-employee directors was as follows:
|
|
Name
|
| |
Number of Stock
Options
|
|
|
John D. Buck
|
| |
-
|
|
|
Alex N. Blanco
|
| |
-
|
|
|
Jody H. Feragen
|
| |
-
|
|
|
Robert C. Frenzel
|
| |
-
|
|
|
Francis J. Malecha
|
| |
-
|
|
|
Ellen A. Rudnick
|
| |
-
|
|
|
Neil A. Schrimsher
|
| |
12,000
|
|
|
Total
|
| |
12,000
|
|
|
Name and Address of Beneficial Owner (a)
|
| |
Amount and Nature
of Beneficial
Ownership (a)
|
| |
Percent of
Class (b)
|
|
|
T. Rowe Price Associates, Inc.
|
| |
13,368,604(c)
|
| |
13.7%
|
|
|
BlackRock, Inc.
|
| |
10,243,209(d)
|
| |
10.5%
|
|
|
Delaware Charter Guarantee & Trust Company dba Principal Trust Company as Directed Trustee for the Patterson Companies, Inc. Employee Stock Ownership Plan
|
| |
10,162,000(e)
|
| |
10.5%
|
|
|
FMR LLC
|
| |
9,413,799(f)
|
| |
9.7%
|
|
|
The Vanguard Group
|
| |
8,379,997(g)
|
| |
8.6%
|
|
|
Mark S. Walchirk
|
| |
704,192(h)(i)
|
| |
*
|
|
|
Donald J. Zurbay
|
| |
310,183(h)(i)
|
| |
*
|
|
|
Les B. Korsh
|
| |
183,617(h)(i)
|
| |
*
|
|
|
Kevin M. Pohlman
|
| |
164,012(h)(i)
|
| |
|
|
|
Eric R. Shirley
|
| |
86,942(h)(i)
|
| |
*
|
|
|
John D. Buck
|
| |
70,203
|
| |
*
|
|
|
Ellen A. Rudnick
|
| |
60,869
|
| |
*
|
|
|
Neil A. Schrimsher
|
| |
38,122(j)
|
| |
*
|
|
|
Jody H. Feragen
|
| |
34,479(k)
|
| |
*
|
|
|
Alex N. Blanco
|
| |
18,634
|
| |
*
|
|
|
Robert C. Frenzel
|
| |
15,576
|
| |
*
|
|
|
Francis J. Malecha
|
| |
15,576
|
| |
*
|
|
|
All current directors and executive officers as a group (13 persons)
|
| |
1,782,301(l)
|
| |
1.8%
|
|
*
|
Represents less than 1%.
|
(a)
|
Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and includes voting or investment power with respect to securities. Securities “beneficially owned” by a person may include securities owned by or for, among others, the spouse, children or certain other relatives of such person as well as other securities as to which the person has or shares voting or investment power or has the option or right to acquire within 60 days. The same shares may be beneficially owned by more than one person. Includes shares of common stock held by our ESOP. Shares reported as owned by the ESOP trustee are also reported as beneficially owned by our executive officers to the extent that shares have been allocated to the ESOP accounts of the named persons. Allocated shares are voted by the ESOP trustee in accordance with the direction of ESOP participants. Generally, unallocated shares and allocated shares as to which no direction is made by the participants are voted by the ESOP trustee in the same percentage as the allocated shares as to which directions are received by the ESOP trustee. Unless otherwise indicated, the address of each shareholder is c/o Patterson Companies, Inc., 1031 Mendota Heights Road, St. Paul, Minnesota 55120.
|
(b)
|
Percentage of beneficial ownership is based on 97,229,896 shares outstanding as of July 16, 2021. Shares issuable pursuant to options are deemed outstanding for computing the percentage of the person holding such options but are not deemed outstanding for computing the percentage of any other person.
|
(c)
|
As set forth in Schedule 13G/A jointly filed with the Securities and Exchange Commission by T. Rowe Price Associates, Inc. (“Price Associates”) and T. Rowe Price Mid-Cap Value Fund, Inc. (“Mid-Cap Value Fund”) on February 16, 2021. The Schedule 13G/A reports that Price Associates is an investment adviser with sole voting power over 4,745,377 shares and sole dispositive power over 13,368,604 shares. The Schedule 13G/A reports that Mid-Cap Value Fund is a registered investment company sponsored by Price Associates, which it also serves as investment adviser, with sole voting power over 8,538,021 shares, representing 8.8% of the class of such securities. The Schedule 13G/A further reports as follows: Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client’s custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, the reported securities. The individual and institutional clients which Price Associates serves as investment adviser have the power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, the reported shares, and any discretionary authority that has been delegated to Price Associates may be revoked in whole or in part at any time. With the exception of Mid-Cap Value Fund, not more than 5% of the security class being reported on the Schedule 13G/A is owned by any one client subject to the investment advice of Price Associates. With respect to securities owned by Mid-Cap Value Fund, only the custodian for such fund has the right to receive dividends paid with respect to, and proceeds from the sale of, the reported securities, and that no other person is known to have such right, except that the shareholders of the Mid-Cap Value Fund participate proportionately in any dividends and distributions so paid. The reporting persons’ address is 100 E. Pratt Street, Baltimore, MD 21202.
|
(d)
|
As set forth in Schedule 13G/A filed with the Securities and Exchange Commission by BlackRock, Inc. (“BlackRock”) on January 27, 2021. The Schedule 13G/A reports that BlackRock is a parent holding company/control person for BlackRock Life Limited, BlackRock Advisors, LLC, BlackRock (Netherlands) B.V., BlackRock Fund Advisors (which entity beneficially owns 5% or greater of the outstanding shares of the security class being reported on the Schedule 13G/A), BlackRock Institutional Trust Company, National Association, BlackRock Asset Management Ireland Limited, BlackRock Financial Management, Inc., BlackRock Japan Co., Ltd., BlackRock Asset Management Schweiz AG, BlackRock Investment Management, LLC, BlackRock Investment Management (UK) Limited, BlackRock Asset Management Canada Limited, BlackRock (Luxembourg) S.A., BlackRock Investment Management (Australia) Limited, and BlackRock Fund Managers Ltd. The Schedule 13G/A reports that BlackRock has sole voting power over 9,992,557 shares and sole dispositive power over 10,243,209 shares. The Schedule 13G/A further reports that various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the reported shares, but no one person’s interest in the reported shares is more than 5% of the total outstanding shares. The reporting person’s address is 55 East 52nd Street, New York, NY 10055.
|
(e)
|
As set forth in Schedule 13G/A filed with the Securities and Exchange Commission by Delaware Charter Guarantee & Trust Company dba Principal Trust Company as Directed Trustee for the Patterson Companies, Inc. Employee Stock Ownership Plan (“ESOP”) on February 11, 2021. The Schedule 13G/A reports as follows: The reported shares represent shares over which shared voting power and shared dispositive power is claimed. The ESOP is subject to the Employee Retirement Income Security Act of 1974 (“ERISA”). Delaware Charter Guarantee & Trust Company dba Principal Trust Company acts as the directed trustee of the ESOP. The securities reported include all shares held of record by the trustee. The trustee follows the directions of our company, or other parties designated in the trust agreement between our company and the trustee, with respect to voting and disposition of the shares. The trustee, however, is subject to fiduciary duties under ERISA. The trustee disclaims beneficial ownership of the reported shares. As of July 16, 2021, the number of shares reported as beneficially owned represented shares held in the allocated account of the ESOP. The reporting person’s address is 1013 Centre Road, Suite 300, Wilmington, DE 19805-1265.
|
(f)
|
As set forth in Schedule 13G filed with the Securities and Exchange Commission by FMR LLC (“FMR”) and Abigail P. Johnson on February 8, 2021. The Schedule 13G reports that FMR is a parent holding company for FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC
|
(g)
|
As set forth in Schedule 13G/A filed with the Securities and Exchange Commission by The Vanguard Group (“Vanguard”) on February 10, 2021. The Schedule 13G reports that Vanguard is a parent holding company for Vanguard Asset Management, Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisors, LLC, Vanguard Group (Ireland) Limited, Vanguard Investments Australia Ltd., Vanguard Investments Canada Inc., Vanguard Investments Hong Kong Limited, and Vanguard Investments UK, Limited. The Schedule 13G/A reports that Vanguard is an investment adviser with sole voting power over no shares, shared voting power over 85,570 shares, sole dispositive power over 8,225,848 shares, and shared dispositive power over 154,149 shares. The reporting person’s address is 100 Vanguard Blvd., Malvern, PA 19355.
|
(h)
|
Includes the following shares allocated to the ESOP account of the following persons: Mark S. Walchirk (1,215 shares); Donald J. Zurbay (1,061 shares); Les B. Korsh (1,976 shares); Kevin M. Pohlman (1,660 shares); and Eric R. Shirley (623 shares). The ESOP trustee has the right to receive, and the power to direct the receipt of, dividends from such shares.
|
(i)
|
Includes shares purchasable by the named person upon the exercise of options granted under our Amended and Restated Equity Incentive Plan, our Amended and Restated 2015 Omnibus Incentive Plan or as inducement awards issued outside such plans: Mark S. Walchirk (374,815 shares); Donald J. Zurbay (204,367 shares); Les B. Korsh 92,115 shares); Kevin M. Pohlman (63,571 shares); and Eric R. Shirley (30,752 shares).
|
(j)
|
Includes 12,000 shares purchasable upon the exercise of options granted under our Amended and Restated Equity Incentive Plan.
|
(k)
|
Of the shares reported as beneficially owned, 1,000 shares are held in a revocable trust of which Ms. Feragen is a trustee.
|
(l)
|
Includes 7,605 shares allocated to ESOP accounts, 815,004 shares purchasable upon the exercise of options, and 473,854 shares over which there is sole voting power but no investment power.
|
|
Named Executive Officer
|
| |
Position
|
|
|
Mark S. Walchirk
|
| |
President and Chief Executive Officer
|
|
|
Donald J. Zurbay
|
| |
Chief Financial Officer and Treasurer
|
|
|
Eric R. Shirley
|
| |
Former President, Patterson Dental*
|
|
|
Les B. Korsh
|
| |
Vice President, General Counsel and Secretary
|
|
|
Kevin M. Pohlman
|
| |
President, Patterson Animal Health
|
|
*
|
Mr. Shirley ceased serving as President of Patterson Dental effective July 19, 2021, at which time he assumed the role of Senior Vice President of Business Development of Patterson Dental.
|
■
|
Fiscal 2021 results As depicted in the table below, consolidated reported net sales for fiscal 2021 were $5.91 billion, a 7.7 percent year-over-year increase.
|
■
|
Balance sheet data. During fiscal 2021, we used $731.1 million of cash from operating activities and collected deferred purchase price receivables of $834.5 million, netting $103.4 million in cash, compared to a total of $297.4 million during fiscal 2020. Free cash flow, which we define as net cash (used in) provided by operating activities less capital expenditures less the one-time benefit from the initiation of our trade accounts receivable facilities plus collection of deferred purchase price receivables, was $77.7 million, which was $148.9 million lower than in fiscal 2020 due to an increased level of working capital during fiscal 2021.
|
■
|
Shareholder Returns. During fiscal 2021, our stock price increased from $16.69 per share on April 25, 2020 to $33.46 per share on April 23, 2021 and we paid more than $75.2 million in dividends to our shareholders. Assuming reinvestment of dividends, the total return to shareholders in fiscal 2021 was 126.8%. The following chart depicts the increase in the market price of our company’s common stock from fiscal year end 2020 to fiscal year end 2021.
|
■
|
Short-Term Incentives. In light of the macroeconomic uncertainty associated with the COVID-19 pandemic, we modified the short-term incentive program for fiscal 2021 in two important ways:
|
■
|
We simplified the performance measurement to create a single, unified focus on firm-wide results. We designed our short-term incentives with an STI pool in which all management, including our named executive officers, were eligible to participate. The funding for the fiscal 2021 Management Incentive Compensation Plan (“MICP”) was based on a percentage of our company’s consolidated adjusted operating income (which we refer to as “adjusted operating income”) for fiscal 2021 with each executive’s target opportunity (expressed as a percentage in relation to his or her fiscal 2021 base salary) in proportional relationship to the total STI pool. The committee determined to subject all executives and other members of management, including business unit presidents and non-business unit leaders, to the
|
■
|
We “flattened the curve” of the incentive payout opportunity, to reflect the difficulty of goal-setting for fiscal 2021 and to minimize the risk of payouts not aligned with performance. By requiring a threshold level of achievement for any payout and graduating the payout scale at increasing levels of adjusted operating income, the committee sought to manage through the macroeconomic uncertainty with a short-term incentive plan that would serve to retain management but only reward management if the shareholders also benefitted. Despite the disruption in early fiscal 2021, we surpassed our adjusted operating income objectives for the full year. As a result, our MICP funded at 145% of target for our named executive officers.
|
■
|
Long-Term Incentives. For fiscal 2021, long-term incentive target opportunities were delivered 50% in performance units and 25% each in stock options and restricted stock units. The performance units are subject to three distinct annual targets, with each year accounting for one-third of the total opportunity. A cumulative relative total shareholder return (“rTSR”) modifier based on the S&P 400 Mid-Cap Index will be applied at the end of the three-year period to adjust the amount conditionally earned up or down, by up to 20%. Although the total number of performance unit awards issued was determined by reference to the value of the award established at the beginning of the three-year cycle, the committee decided, in light of the economic uncertainty at the beginning of fiscal 2021, it would set performance goals at the beginning of each year in the three-year cycle. With respect to the initial one-year performance period, the committee continued its desire to focus the organization on execution and, as such, it determined to utilize the metrics of consolidated adjusted net income (which we refer to as “adjusted net income”) and EBITDA leverage ratio, each weighted 50%. Adjusted net income, for purposes of computing the first-year performance under the fiscal 2021 performance unit awards, is defined as non-GAAP adjusted net income for fiscal 2021 as reported by our company in its earnings release for fiscal 2021, subject to any negative discretion exercised by the committee. EBITDA leverage ratio, for purposes of computing the first year performance under the fiscal 2021 performance units awards, is calculated and defined as the quarterly average of our company’s debt to EBITDA ratio throughout fiscal 2021, with debt and EBITDA measured as defined in our company’s credit agreements with its lenders. For fiscal 2021, we surpassed both our adjusted net income and EBITDA leverage ratio objectives. Performance units for the first year of the three-year cycle therefore funded at 150% of target. Total shares conditionally earned over the three-year cycle do not vest until July 2023 at which time they will be subject to the above-referenced modifier. The stock options vest one-third each year, starting one year after grant, and the restricted stock units vest in full three years after grant.
|
■
|
Establish for executive officers, and recommend to the Board for approval with respect to the chief executive officer, the annual base salary and MICP target opportunity for the current fiscal year
|
■
|
Determine the actual annual incentive compensation to be paid to each executive for services provided during the prior year
|
■
|
Establish for executive officers, and recommend to the Board for approval with respect to the chief executive officer, plan targets and performance measures for the performance period for performance units
|
■
|
Determine the number of performance units earned, if any, under the long-term incentive program for the performance period ending with the prior fiscal year
|
■
|
Determine restricted stock units and stock option awards and any other equity-based awards to be granted to executive officers
|
|
Fiscal 2021 Peer Group
|
| ||||||
|
Anixter International Inc.
|
| |
HD Supply Holdings, Inc.
|
| |
Pool Corp.
|
|
|
Applied Industrial Technologies, Inc.
|
| |
Henry Schein, Inc.
|
| |
W.W. Grainger, Inc.
|
|
|
Beacon Roofing Supply, Inc.
|
| |
Hill-Rom Holdings, Inc.
|
| |
Watsco, Inc.
|
|
|
Covetrus, Inc.
|
| |
MRC Global Inc.
|
| |
WESCO International Inc.
|
|
|
DENTSPLY SIRONA Inc.
|
| |
MSC Industrial Direct Co. Inc.
|
| |
|
|
|
Fastenal Company
|
| |
Owens & Minor Inc.
|
| |
|
|
|
What We Do
|
| |
What We Do Not Do
|
| ||||||
|
✔
|
| |
Position target executive pay levels generally at the peer median
|
| |
✘
|
| |
Provide single trigger change-in-control cash severance payments, or change-in-control cash severance payments exceeding three times base salary and target annual incentives
|
|
|
✔
|
| |
Deliver the majority of our compensation in variable pay elements
|
| |
✘
|
| |
Allow stock option repricing, discounted stock option granting, or cash out of underwater options
|
|
|
✔
|
| |
Use equity with multi-year vesting requirements to drive alignment with shareholders
|
| |
✘
|
| |
Provide reload provisions in stock option grants
|
|
|
✔
|
| |
Promote stock ownership with executive and director stock ownership guidelines
|
| |
✘
|
| |
Offer change-in-control tax gross-ups to our named executive officers
|
|
|
✔
|
| |
Reflect shareholder preferences in our program plans and designs, including clawback and double trigger protections
|
| |
✘
|
| |
Pay dividends or dividend equivalents on unearned performance units or unvested restricted stock units
|
|
|
✔
|
| |
Cap payouts in our short-term incentive plan
|
| |
✘
|
| |
Allow our executives or directors to hedge or pledge company stock
|
|
|
✔
|
| |
Review our pay for performance relationship annually
|
| |
|
| |
|
|
|
✔
|
| |
Conduct a compensation risk assessment
|
| |
|
| |
|
|
|
Element
|
| |
Purpose
|
| |
Key Features
|
|
|
Annual Base Salary
|
| |
■ Provide a fixed level of compensation
■ Reflect competitive practices |
| |
■ Set salary levels based on an assessment of:
■ Level of responsibility ■ Experience and time in position ■ Individual performance ■ Future potential ■ Competitiveness ■ Internal pay equity considerations
■ Salary levels are reviewed annually by the committee and adjusted as appropriate
|
|
|
Annual Short-Term Incentive Compensation
|
| |
■ Designed with the uncertainties stemming from COVID-19 in mind, tied short-term incentives for executive officers and other members of management to adjusted operating income for fiscal 2021
■ Eliminated individual performance objectives for fiscal 2021 in the spirit of “we’re in this together”
■ Linked pay to corporate performance
|
| |
■ Simple design framework given the uncertainty of operating in a pandemic-driven environment
■ Performance results below $85 million in adjusted operating income would have resulted in no payout for fiscal 2021
■ Reduced the upside payout leverage to reflect the difficulty of goal-setting
|
|
|
Annual Long-Term Incentive Compensation – Performance Units
|
| |
■ Provide executive officers with incentives to achieve long-term success through performance-based equity compensation with multi-year vesting requirements
■ Align executive officers’ interests with the interests of our shareholders
|
| |
■ Fiscal 2019 and 2020 grants based 50% on 1-year free cash flow and 50% on 1-year adjusted net income with a 2-year cliff vesting restriction at the end of the 1-year performance period
■ Fiscal 2021 grants based on three annual performance targets and financial metrics then subject to an rTSR modifier; first year performance objectives based 50% on 1-year adjusted net income and 50% on 1-year EBITDA leverage ratio
|
|
|
Annual Long-Term Incentive Compensation – Stock Options
|
| |
■ Align executive officers’ interests with those of shareholders through a focus on stock price performance and shareholder value creation
|
| |
■ 10-year term
■ 3-year ratable vesting |
|
|
Annual Long-Term Incentive Compensation – Restricted Stock Units (“RSUs”)
|
| |
■ Provide opportunities for equity accumulation and alignment with shareholders
■ Support leadership retention objectives
|
| |
■ 3-year cliff vesting
|
|
|
Executive
|
| |
Fiscal 2020
Base Salary
|
| |
Temporary Base Salary
Reduction
Percentage
|
| |
Fiscal 2021
Base Salary (Effective
January 1, 2021)
|
| |
Percentage
Increase
(FY21 over FY20)
|
|
|
Mark S. Walchirk
|
| |
$875,000
|
| |
35%
|
| |
$925,000
|
| |
5.7%
|
|
|
Donald J. Zurbay
|
| |
$541,000
|
| |
30%
|
| |
$557,200
|
| |
3.0%
|
|
|
Eric R. Shirley
|
| |
$457,000
|
| |
30%
|
| |
$468,400
|
| |
2.5%
|
|
|
Les B. Korsh
|
| |
$412,000
|
| |
30%
|
| |
$424,400
|
| |
3.0%
|
|
|
Kevin M. Pohlman
|
| |
$373,000
|
| |
30%
|
| |
$410,300
|
| |
10.0%
|
|
■
|
Disruptions in the company’s supply chains from shipping delays, which impacted goal calibration for both of our business segments;
|
■
|
Guidance from federal, state, and local governmental bodies and industry associations that routine dental care and routine veterinary care should be deferred, which impacted goal calibration for both of our business segments;
|
■
|
Information from a leading dental association that more than 95% of dentists were reporting either seeing emergency patients only or not seeing any patients, which impacted goal calibration for our dental segment; and
|
■
|
Uncertain impact on meat packing operations, which impacted goal calibration for our animal health segment.
|
■
|
Setting performance targets in this climate that it believed were aligned with opportunities to reduce spending, increase efficiencies, maintain profitability, and opportunistically grow certain products and services;
|
■
|
Avoiding compensation windfalls from setting maximum performance goals too conservatively if the pandemic’s impact was negligible; and
|
■
|
Preventing the loss of motivational value from setting minimum performance goals too aggressively if the pandemic’s impact was severe in both magnitude and duration.
|
|
Level of
Funding
|
| |
Adjusted Operating
Income ($M)
(100% weight)
|
| |
Percent of Adjusted
Operating Income for
MICP Pool
|
| |
Calculation ($M)
|
| |
Actual MICP
Pool ($M)
|
|
|
None
|
| |
Less than $85
|
| |
0.0%
|
| |
0
|
| |
$0
|
|
|
In-the-Money
|
| |
$85 – $200
|
| |
15.0%
|
| |
$200 x 15.0%
|
| |
$30
|
|
|
Excess
|
| |
Over $200
|
| |
12.5%
|
| |
$47.6 x 12.5%
|
| |
$5.95
|
|
|
Actual Outcome
|
| |
$247.6*
|
| |
|
| |
|
| |
$35.95
|
|
*
|
Represents reported adjusted operating income of $248.7 million that the committee determined to exercise negative discretion to exclude the benefit of $1.1 million in certain non-GAAP costs and expenses.
|
■
|
The MICP was designed in respect of the economic uncertainty that existed when the plan was designed and goals were set;
|
■
|
Although the company significantly outperformed its performance forecasts, the conservative payout slope prevented a management incentive compensation windfall; and
|
■
|
The company’s fiscal 2021 total shareholder return of 126.8% aligned with an above-target MICP funding result.
|
|
Executive
|
| |
Fiscal 2021 Base
Salary
|
| |
MICP Target
Award % of
Base Salary
|
| |
Target MICP
Award
|
| |
Payment as
a % of
Target
|
| |
Total MICP
Payment
|
|
|
Mark S. Walchirk
|
| |
$925,000
|
| |
124%
|
| |
$1,147,000
|
| |
145%
|
| |
$1,663,150
|
|
|
Donald J. Zurbay
|
| |
$557,200
|
| |
85%
|
| |
$473,600
|
| |
145%
|
| |
$686,720
|
|
|
Eric R. Shirley
|
| |
$468,400
|
| |
60%
|
| |
$281,000
|
| |
145%
|
| |
$407,450
|
|
|
Les B. Korsh
|
| |
$424,400
|
| |
60%
|
| |
$254,600
|
| |
145%
|
| |
$369,170
|
|
|
Kevin M. Pohlman
|
| |
$410,300
|
| |
60%
|
| |
$246,200
|
| |
145%
|
| |
$356,990
|
|
|
Executive
|
| |
Performance
Units
($ / #)
|
| |
Stock Options
($ / #)
|
| |
Restricted Stock
Units
($ / #)
|
| |
Total
($)
|
|
|
Mark S. Walchirk
|
| |
$1,625,000
|
| |
$822,487
|
| |
$812,505
|
| |
$3,259,992
|
|
|
68,944
|
| |
178,965
|
| |
34,472
|
| |
|
| |||
|
|
| |
|
| |
|
| |
|
| |
|
|
|
Donald J. Zurbay
|
| |
$525,000
|
| |
$265,725
|
| |
$262,499
|
| |
$1,053,224
|
|
|
22,275
|
| |
57,819
|
| |
11,137
|
| |
|
| |||
|
|
| |
|
| |
|
| |
|
| |
|
|
|
Eric R. Shirley
|
| |
$225,000
|
| |
$113,884
|
| |
$112,500
|
| |
$451,384
|
|
|
9,546
|
| |
24,780
|
| |
4,773
|
| |
|
| |||
|
|
| |
|
| |
|
| |
|
| |
|
|
|
Les B. Korsh
|
| |
$225,000
|
| |
$113,884
|
| |
$112,500
|
| |
$451,384
|
|
|
9,546
|
| |
24,780
|
| |
4,773
|
| |
|
| |||
|
|
| |
|
| |
|
| |
|
| |
|
|
|
Kevin M. Pohlman
|
| |
$225,000
|
| |
$113,884
|
| |
$112,500
|
| |
$451,384
|
|
|
9,546
|
| |
24,780
|
| |
4,773
|
| |
|
|
|
Relative TSR Modifier
|
| |
|
|
|
If Patterson’s relative TSR is:
|
| |
Then the conditionally earned amounts are:
|
|
|
At or below the 30th percentile
|
| |
Adjusted down by 20%
|
|
|
At or above the 75th percentile
|
| |
Increased by 20%
|
|
*
|
The maximum payout for the first year of the fiscal 2021 performance units is 150%. For the second and third performance measurement years of such awards the maximum payout is 175%.
|
■
|
Chief Executive Officer – 5x annual base salary
|
■
|
All Direct Reports to the Chief Executive Officer – 3x annual base salary
|
■
|
Non-Employee Directors – 5x annual cash retainer
|
■
|
Automobile Reimbursement: Formerly, each executive employed by Patterson was provided the use of a car under the fleet program maintained by our company. Effective January 1, 2021, Patterson no longer offers an executive automobile lease or any other vehicle allowance to anyone newly hired or promoted to a Vice President position or above. Nevertheless, executives who are currently under a vehicle lease were “grandfathered” into the program and remain eligible for the executive car program with certain program modifications. In particular, the ability to purchase leased cars at the end of the lease for a processing fee will be discontinued for any lease ending on or after January 1, 2023. Instead, the executive may purchase their current vehicle under such a lease by paying the fair market value of the vehicle as determined by a general industry-accepted valuation source.
|
■
|
Executive Physicals: The executives are encouraged to participate in an executive health program at the Mayo Clinic. A comprehensive evaluation emphasizing all aspects of preventative care is conducted by physicians who are specialists in Internal Medicine and Preventative Medicine. The cost of the physical is reimbursed by our company.
|
■
|
Executive Life Insurance Premiums: The executives participate in a company-sponsored executive life insurance program. This program provides our named executive officers with a life insurance benefit equal to three times their base salary plus the targeted annual incentive under the MICP. The life insurance benefit is capped at $1,300,000. Premiums, which are set each June, are paid by our company through a payroll gross-up.
|
■
|
Amounts Reimbursed for the Payment of Taxes: Patterson pays an amount necessary to cover executives’ tax obligations for certain perquisites and other personal benefits. In fiscal 2021, Patterson reimbursed executives for the payment of taxes on automobile reimbursement, executive life insurance premiums and commuting expenses.
|
■
|
Company Contributions to the ESOP: Through and including fiscal 2021, our company made an annual contribution to the leveraged Employee Stock Ownership Plan (“ESOP”) based on company performance and other considerations equal to a certain percentage of an executive’s eligible compensation, subject to certain statutory limitations. This contribution was available generally to all our U.S. employees, subject to plan requirements. In June 2021, the committee determined to suspend the ESOP for any new participants. For fiscal 2022, contributions will be made to the company’s 401(k) instead of the ESOP.
|
■
|
Incentive Trips: Expenses incurred by the executive and family members while attending special events or trips scheduled as rewards for incentivizing sales or other business achievements and for family members traveling with the executive for any purpose, are reported as imputed income to the executive.
|
■
|
Commuting Expenses: Patterson pays amounts necessary to cover the commuting expenses of one named executive officer who resides in locations other than in the Minneapolis/St. Paul metropolitan area.
|
■
|
18 months of base salary (24 months in the case of our President and Chief Executive Officer);
|
■
|
Cash incentive compensation equal to an average of the last three years of actual MICP incentives;
|
■
|
Proration of the current year MICP incentive based on actual performance; and
|
■
|
18 months of paid COBRA premiums.
|
■
|
We terminate the executive’s employment with us for a reason other than cause (as defined in the agreement), or
|
■
|
The executive terminates his or her employment with us for good reason (as defined in the agreement).
|
■
|
24 months of base salary (36 months in the case of our President and Chief Executive Officer);
|
■
|
Cash incentive compensation equal to the then-current target MICP incentive;
|
■
|
Proration of the current year MICP incentive based on target performance; and
|
■
|
18 months of paid COBRA premiums.
|
■
|
Our Amended and Restated Equity Incentive Plan, under which no new awards may be granted, provides that awards issued under that plan are fully vested and all restrictions on the awards lapse in the event of a change in control, as defined in such plan.
|
■
|
Under our Amended and Restated 2015 Omnibus Incentive Plan, if the surviving or acquiring company in a change in control assumes our company’s outstanding incentive awards or provides for their equivalent substitutes, such plan provides for accelerated vesting of incentive awards following a change in control only upon the termination of the employee’s service, a material reduction in an employee’s base salary, a discontinuation of participation in certain long-term cash or equity benefits provided to comparable employees, a significant change in job responsibilities or the need to relocate, provided these events occur within two years of a change in control. The inducement awards issued outside our equity plans provide for the same change-in-control benefits.
|
|
Name and Principal Position (a)
|
| |
Fiscal
Year
|
| |
Salary
($)(b)
|
| |
Bonus
($)
|
| |
Stock
Awards
($) (c)
|
| |
Option
Awards
($)
|
| |
Non-Equity
Incentive
Plan
Compen-
sation
($) (d)
|
| |
Change in
Pension Value
and Non-
qualified
Deferred
Compensation
Earnings ($)
|
| |
All Other
Compensation
($) (e)
|
| |
Total
($)
|
|
|
Mark S. Walchirk
|
| |
2021
|
| |
802,658
|
| |
-
|
| |
1,359,111
|
| |
822,487
|
| |
1,663,150
|
| |
-
|
| |
110,439
|
| |
4,757,845
|
|
|
President and Chief Executive
|
| |
2020
|
| |
870,840
|
| |
-
|
| |
2,437,510
|
| |
824,383
|
| |
1,600,375
|
| |
-
|
| |
126,396
|
| |
5,859,504
|
|
|
Officer
|
| |
2019
|
| |
850,005
|
| |
-
|
| |
2,361,346
|
| |
336,472
|
| |
656,250
|
| |
-
|
| |
204,558
|
| |
4,408,631
|
|
|
Donald J. Zurbay
|
| |
2021
|
| |
498,328
|
| |
-
|
| |
439,080
|
| |
265,725
|
| |
686,720
|
| |
-
|
| |
91,546
|
| |
1,981,398
|
|
|
Chief Financial Officer and
|
| |
2020
|
| |
538,388
|
| |
-
|
| |
787,517
|
| |
266,340
|
| |
671,381
|
| |
-
|
| |
58,792
|
| |
2,322,418
|
|
|
Treasurer
|
| |
2019
|
| |
439,522
|
| |
-
|
| |
1,453,341
|
| |
453,667
|
| |
278,906
|
| |
-
|
| |
24,080
|
| |
2,649,516
|
|
|
Eric R. Shirley
|
| |
2021
|
| |
420,222
|
| |
-
|
| |
188,177
|
| |
113,884
|
| |
407,450
|
| |
-
|
| |
22,849
|
| |
1,152,582
|
|
|
Former President, Patterson Dental
|
| |
2020
|
| |
455,837
|
| |
-
|
| |
337,488
|
| |
114,146
|
| |
345,492
|
| |
-
|
| |
34,574
|
| |
1,287,537
|
|
|
Les B. Korsh
|
| |
2021
|
| |
379,523
|
| |
-
|
| |
188,177
|
| |
113,884
|
| |
369,170
|
| |
-
|
| |
89,453
|
| |
1,140,206
|
|
|
Vice President, General Counsel
|
| |
2020
|
| |
410,003
|
| |
-
|
| |
337,488
|
| |
114,146
|
| |
346,080
|
| |
|
| |
50,739
|
| |
1,258,456
|
|
|
and Secretary
|
| |
2019
|
| |
390,003
|
| |
|
| |
1,820,145
|
| |
47,292
|
| |
141,000
|
| |
|
| |
37,490
|
| |
2,435,930
|
|
|
Kevin M. Pohlman
|
| |
2021
|
| |
351,937
|
| |
-
|
| |
188,177
|
| |
113,884
|
| |
356,990
|
| |
-
|
| |
103,916
|
| |
1,114,904
|
|
|
President,
|
| |
2020
|
| |
369,170
|
| |
-
|
| |
337,488
|
| |
114,146
|
| |
257,370
|
| |
-
|
| |
41,469
|
| |
1,119,643
|
|
|
Patterson Animal Health
|
| |
2019
|
| |
341,669
|
| |
-
|
| |
1,551,316
|
| |
44,922
|
| |
162,750
|
| |
-
|
| |
43,839
|
| |
2,144,496
|
|
(a)
|
Mr. Walchirk, who also serves as one of our directors, became our President and Chief Executive Officer in November 2017. Mr. Zurbay became our Chief Financial Officer and Treasurer in June 2018. Mr. Shirley became President of Patterson Dental in January 2019 and transitioned into the role of Senior Vice President of Business Development of Patterson Dental in July 2021. Mr. Korsh became our Vice President, General Counsel and Secretary in July 2015. Mr. Pohlman became President of Patterson Animal Health in July 2017.
|
(b)
|
Includes amounts foregone at the election of the executive pursuant to The Executive Nonqualified Excess Plan. Further information regarding such amounts is reported in the Nonqualified Deferred Compensation Table below.
|
(c)
|
Represents the aggregate grant date fair value of restricted stock units and performance units assuming target performance computed in accordance with FASB ASC Topic 718. Information on the assumptions used to calculate such value is set forth in Note 15 to the consolidated financial statements in our Annual Report on Form 10-K for the fiscal year ended April 24, 2021. For the 2021 awards, as the performance units are based on separate measurements of our company’s financial performance for each year in the three-year performance cycle and goals for the second and third years in the cycle were not yet set, FASB ASC Topic 718 requires the grant date fair value to be calculated for the portion of the award attributable to fiscal 2021 performance; however, the company considers the second and third year of the fiscal 2021 performance unit grants that will be disclosed in future proxy statements as part of the fiscal 2021 long-term incentive opportunity. Therefore, the value presented includes one-third of the target performance units for the FY21 grant. For more details on how performance is calculated, please see “Compensation Discussion and Analysis – Compensation Decisions – Long-Term Incentives” in this proxy statement. The grant date fair value of the performance-related component is based upon the probable outcome for the award and is consistent with the estimate of aggregate compensation cost to be recognized over the performance period determined as of the grant date under FASB ASC Topic 781. Additionally, for the FY21 grant, as required under FASB ASC Topic 718, the full grant date fair value of the rTSR modifier for the entire three-year performance cycle is included in the amounts shown and was determined using a Monte Carlo valuation model on the date the
|
(d)
|
Represents cash compensation earned under our MICP.
|
(e)
|
All other compensation for fiscal 2021 was as set forth in the table below. In addition, infrequently, a family member may accompany an executive traveling on a prepaid corporate flight to a specific destination for business purposes at no incremental cost to our company.
|
|
Name
|
| |
Automobile
Reimburse-
ment
($)*
|
| |
Executive
Physicals
($)
|
| |
Executive
Life
Insurance
Premiums
($)
|
| |
Reimburse-
ment
for the
Payment
of Taxes
($)
|
| |
Company
Contribu-
tions to
ESOP
($)
|
| |
Incentive
Trips
($)
|
| |
Commuting
Expenses
($)
|
| |
Dividends
($)
|
| |
Total
($)
|
|
|
Mark S. Walchirk
|
| |
13,473
|
| |
-
|
| |
5,616
|
| |
8,445
|
| |
10,376
|
| |
-
|
| |
-
|
| |
72,529
|
| |
110,439
|
|
|
Donald J. Zurbay
|
| |
14,283
|
| |
-
|
| |
6,016
|
| |
8,951
|
| |
10,376
|
| |
-
|
| |
-
|
| |
51,919
|
| |
91,546
|
|
|
Eric R. Shirley
|
| |
-
|
| |
-
|
| |
5,757
|
| |
3,517
|
| |
10,376
|
| |
-
|
| |
3,199
|
| |
-
|
| |
22,849
|
|
|
Les B. Korsh
|
| |
14,277
|
| |
-
|
| |
5,142
|
| |
8,562
|
| |
10,376
|
| |
-
|
| |
-
|
| |
51,095
|
| |
89,453
|
|
|
Kevin M. Pohlman
|
| |
37,750
|
| |
-
|
| |
5,887
|
| |
6,506
|
| |
10,376
|
| |
-
|
| |
-
|
| |
43,397
|
| |
103,916
|
|
*
|
Includes fair market value of automobile purchased by Mr. Pohlman at the end of the lease for a processing fee of $500.
|
|
|
| |
|
| |
|
| |
|
| |
Estimated Possible Payouts
Under Non-Equity Incentive
Plan Awards (c)
|
| |
|
| |
Estimated Future Payouts
Under Equity Incentive
Plan Awards (d)
|
| |
All
Other
Stock
Awards:
Number
of
Shares
of Stock
or Units
(#) (e)
|
| |
All
Other
Option
Awards:
Number
of
Securities
Underlying
Options
(#) (f)
|
| |
Exercise
or Base
Price of
Option
Awards
($/Sh)
|
| |
Grant
Date Fair
Value of
Stock and
Option
Awards
($) (g)
|
| ||||||||||||
|
Name
|
| |
Type
of
Grant
(a)
|
| |
Grant
Date
|
| |
Date
of
Action
(b)
|
| |
Thresh-
old
($)
|
| |
Target
($)
|
| |
Maximum
($)
|
| |
|
| |
Thresh-
old
(#)
|
| |
Target
(#)
|
| |
Maximum
(#)
|
| ||||||||||||
|
Mark S. Walchirk
|
| |
MICP
|
| |
7/31/2020
|
| |
7/1/2020
|
| |
573,500
|
| |
1,147,000
|
| |
2,007,250
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
PSU
|
| |
9/29/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
9,101
|
| |
22,752
|
| |
45,504
|
| |
-
|
| |
-
|
| |
-
|
| |
546,606
|
| |||
|
RSU
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
34,472
|
| |
-
|
| |
-
|
| |
812,505
|
| |||
|
SO
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
178,965
|
| |
23.57
|
| |
822,487
|
| |||
|
Donald J. Zurbay
|
| |
MICP
|
| |
7/31/2020
|
| |
7/1/2020
|
| |
236,810
|
| |
473,620
|
| |
828,835
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
PSU
|
| |
9/29/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
2,940
|
| |
7,350
|
| |
14,700
|
| |
-
|
| |
-
|
| |
-
|
| |
176,581
|
| |||
|
RSU
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
11,137
|
| |
-
|
| |
-
|
| |
262,499
|
| |||
|
SO
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
57,819
|
| |
23.57
|
| |
265,725
|
| |||
|
Eric R.
Shirley
|
| |
MICP
|
| |
7/31/2020
|
| |
7/1/2020
|
| |
140,520
|
| |
281,040
|
| |
491,820
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
PSU
|
| |
9/29/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
1,260
|
| |
3,150
|
| |
6,300
|
| |
-
|
| |
-
|
| |
-
|
| |
75,677
|
| |||
|
RSU
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
4,773
|
| |
-
|
| |
-
|
| |
112,500
|
| |||
|
SO
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
24,780
|
| |
23.57
|
| |
113,884
|
| |||
|
Les B.
Korsh
|
| |
MICP
|
| |
7/31/2020
|
| |
7/1/2020
|
| |
127,320
|
| |
254,640
|
| |
445,620
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
PSU
|
| |
9/29/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
1,260
|
| |
3,150
|
| |
6,300
|
| |
-
|
| |
-
|
| |
-
|
| |
75,677
|
| |||
|
RSU
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
4,773
|
| |
-
|
| |
-
|
| |
112,500
|
| |||
|
SO
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
- -
|
| |
-
|
| |
-
|
| |
24,780
|
| |
23.57
|
| |
113,884
|
| |||
|
Kevin M. Pohlman
|
| |
MICP
|
| |
7/31/2020
|
| |
7/1/2020
|
| |
123,090
|
| |
246,180
|
| |
430,815
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
PSU
|
| |
9/29/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
1,260
|
| |
3,150
|
| |
6,300
|
| |
-
|
| |
-
|
| |
-
|
| |
75,677
|
| |||
|
RSU
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
4,773
|
| |
-
|
| |
-
|
| |
112,500
|
| |||
|
SO
|
| |
7/14/2020
|
| |
7/14/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
24,780
|
| |
23.57
|
| |
113,884
|
|
(a)
|
“MICP” means estimated possible payout of annual incentive compensation under the MICP. “PSU” means estimated future payout under performance unit. “RSU” means restricted stock unit award. “SO” means stock options.
|
(b)
|
Represents date on which values of the awards were approved by the Compensation Committee.
|
(c)
|
Represents amounts that could have been paid under the MICP for service rendered during fiscal 2021.
|
(d)
|
Represents range of possible performance unit payouts for the three-year performance cycle beginning in fiscal 2021; earned performance units are paid in common stock, which is subject to application of an rTSR modifier at the end of the three-year performance cycle. Our performance units are discussed under the caption “Compensation Discussion and Analysis – Compensation Decisions – Long-Term Incentives” in this proxy statement.
|
(e)
|
Represents restricted stock units which vest in full three years after grant. Dividends declared and paid on shares of our common stock are accrued at the same rate, as dividend equivalents, on these restricted stock units. Accrued amounts are forfeitable and not paid until the related award vests. No preferential dividends are paid on such awards.
|
(f)
|
Represents stock options which vest one-third each year, starting one year after grant.
|
(g)
|
Represents the grant date fair value of performance units, restricted stock units and stock options awarded to each named executive officer, computed in accordance with FASB ASC Topic 718. Amounts included for performance units are based on performance achievement for solely the fiscal 2021 portion of the three-year performance cycle. As required under FASB ASC Topic 718, these amounts include the value of the award contingent upon our company’s financial performance and the full grant date fair value for the rTSR modifier. See footnote (c) to the Summary Compensation Table in this proxy statement for further details.
|
|
|
| |
|
| |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
|
Name
|
| |
Grant
Date
|
| |
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
| |
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
| |
Option
Exercise
Price
($)
|
| |
Option
Expiration
Date
|
| |
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
|
| |
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested ($)
|
| |
Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights
That Have
Not Vested
(#)
|
| |
Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)
|
|
|
Mark S.Walchirk
|
| |
9/29/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
68,944(a)
|
| |
2,306,866
|
|
|
|
| |
7/14/2020
|
| |
-
|
| |
178,965(b)
|
| |
23.57
|
| |
7/14/2030
|
| |
34,472(c)
|
| |
1,153,433
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
81,250(b)
|
| |
162,744(b)
|
| |
22.25
|
| |
7/1/2029
|
| |
36,517(c)
|
| |
1,221,859
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
104,074(d)
|
| |
3,482,331
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2018
|
| |
-
|
| |
99,956(e)
|
| |
22.48
|
| |
7/1/2028
|
| |
21,380(f)
|
| |
715,375
|
| |
-
|
| |
-
|
|
|
|
| |
12/1/2017
|
| |
52,764(e)
|
| |
-
|
| |
35.41
|
| |
12/1/2027
|
| |
3,648(f)
|
| |
122,062
|
| |
-
|
| |
-
|
|
|
Donald J.Zurbay
|
| |
9/29/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
22,274(a)
|
| |
745,288
|
|
|
|
| |
7/14/2020
|
| |
-
|
| |
57,819(b)
|
| |
23.57
|
| |
7/14/2030
|
| |
11,137(c)
|
| |
372,644
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
26,250(b)
|
| |
52,579(b)
|
| |
22.25
|
| |
7/1/2029
|
| |
11,798(c)
|
| |
394,761
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
33,625(d)
|
| |
1,125,103
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2018
|
| |
-
|
| |
33,363(e)
|
| |
22.48
|
| |
7/1/2028
|
| |
6,673(f)
|
| |
223,279
|
| |
-
|
| |
-
|
|
|
|
| |
6/29/2018
|
| |
66,100(b)
|
| |
33,150(b)
|
| |
22.67
|
| |
6/29/2018
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Eric R. Shirley
|
| |
9/29/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
9,546(a)
|
| |
319,409
|
|
|
|
| |
7/14/2020
|
| |
-
|
| |
24,780(b)
|
| |
23.57
|
| |
7/14/2030
|
| |
4,773(c)
|
| |
159,705
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
11,250(b)
|
| |
22,534(b)
|
| |
22.25
|
| |
7/1/2029
|
| |
5,056(c)
|
| |
169,174
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
14,410(d)
|
| |
482,145
|
| |
-
|
| |
-
|
|
|
|
| |
2/4/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
26,607(c)
|
| |
890,270
|
| |
-
|
| |
-
|
|
|
Les B. Korsh
|
| |
9/29/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
9,546(a)
|
| |
319,409
|
|
|
|
| |
7/14/2020
|
| |
-
|
| |
24,780(b)
|
| |
23.57
|
| |
7/14/2030
|
| |
4,773(c)
|
| |
159,705
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
11,250(b)
|
| |
22,534(b)
|
| |
22.25
|
| |
7/1/2029
|
| |
5,056(c)
|
| |
169,174
|
| |
-
|
| |
-
|
|
|
|
| |
|
| |
Option Awards
|
| |
Stock Awards
|
| ||||||||||||||||||
|
Name
|
| |
Grant
Date
|
| |
Number of
Securities
Underlying
Unexercised
Options
(#)
Exercisable
|
| |
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
|
| |
Option
Exercise
Price
($)
|
| |
Option
Expiration
Date
|
| |
Number of
Shares or
Units of
Stock That
Have Not
Vested
(#)
|
| |
Market
Value of
Shares or
Units of
Stock That
Have Not
Vested ($)
|
| |
Equity
Incentive Plan
Awards:
Number of
Unearned
Shares, Units
or Other
Rights
That Have
Not Vested
(#)
|
| |
Equity
Incentive Plan
Awards:
Market or
Payout Value
of Unearned
Shares, Units
or Other
Rights That
Have Not
Vested
($)
|
|
|
|
| |
7/1/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
14,410(d)
|
| |
482,145
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2018
|
| |
-
|
| |
14,179(e)
|
| |
22.48
|
| |
7/1/2028
|
| |
2,836(f)
|
| |
94,893
|
| |
-
|
| |
-
|
|
|
|
| |
6/11/2018
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
33,753(g)
|
| |
1,129,375
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2017
|
| |
11,845(e)
|
| |
-
|
| |
47.51
|
| |
7/1/2027
|
| |
895(f)
|
| |
29,947
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2016
|
| |
10,379(e)
|
| |
-
|
| |
48.47
|
| |
7/1/2026
|
| |
351(f)
|
| |
11,744
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2015
|
| |
25,000(h)
|
| |
-
|
| |
56.66
|
| |
7/1/2025
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Kevin M. Pohlman
|
| |
9/29/2020
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
9,546(a)
|
| |
319,409
|
|
|
|
| |
7/14/2020
|
| |
-
|
| |
24,780(b)
|
| |
23.57
|
| |
7/14/2030
|
| |
4,631(c)
|
| |
154,953
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
11,250(b)
|
| |
22,534(b)
|
| |
22.25
|
| |
7/1/2029
|
| |
5,056(c)
|
| |
169,174
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2019
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
14,410(d)
|
| |
482,145
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2018
|
| |
-
|
| |
13,345(e)
|
| |
22.48
|
| |
7/1/2028
|
| |
2,670(f)
|
| |
89,338
|
| |
-
|
| |
-
|
|
|
|
| |
6/11/2018
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
28,127(g)
|
| |
941,129
|
| |
-
|
| |
-
|
|
|
|
| |
8/7/2017
|
| |
5,539(e)
|
| |
-
|
| |
39.23
|
| |
8/7/2027
|
| |
382(f)
|
| |
12,782
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2017
|
| |
13,935(e)
|
| |
-
|
| |
47.51
|
| |
7/1/2027
|
| |
1,053(f)
|
| |
35,233
|
| |
-
|
| |
-
|
|
|
|
| |
7/1/2016
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
465(f)
|
| |
15,559
|
| |
-
|
| |
-
|
|
(a)
|
Represents unearned performance units subject to three annual performance periods and a rTSR modifier, which vest three years after grant. Presented at target value.
|
(b)
|
Represents nonqualified stock options, which vest one-third each year, starting one year after grant.
|
(c)
|
Represents restricted stock units, which vest in full three years after grant.
|
(d)
|
Represents restricted stock unit equivalents, which vest in full three years after grant.
|
(e)
|
Represents nonqualified stock options, which vest in full three years after grant.
|
(f)
|
Represents restricted stock units, which vest 20% each year, starting one year after grant.
|
(g)
|
Represents restricted stock units, which vest 25% one year after grant, another 25% two years after grant and the remaining 50% three years after grant.
|
(h)
|
Represents nonqualified stock options, which vest 25% one year after grant, another 25% two years after grant and the remaining 50% three years after grant.
|
|
|
| |
Option Awards
|
| |
Stock Awards
|
| ||||||
|
Name
|
| |
Number of Shares
Acquired on Exercise
(#)
|
| |
Value Realized on
Exercise
($)
|
| |
Number of Shares
Acquired on Vesting
(#)
|
| |
Value Realized on
Vesting
($)
|
|
|
Mark S. Walchirk
|
| |
-
|
| |
-
|
| |
76,818
|
| |
2,396,478
|
|
|
Donald J. Zurbay
|
| |
-
|
| |
-
|
| |
37,125
|
| |
1,048,216
|
|
|
Eric R. Shirley
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Les B. Korsh
|
| |
-
|
| |
-
|
| |
28,331
|
| |
638,752
|
|
|
Kevin M. Pohlman
|
| |
-
|
| |
-
|
| |
25,875
|
| |
594,569
|
|
|
Name
|
| |
Executive
Contributions
in Last
FY
($) (a)
|
| |
Registrant
Contributions
in Last
FY
($) (b)
|
| |
Aggregate
Earnings
in Last FY
($) (c)
|
| |
Aggregate
Withdrawals/
Distributions
($)
|
| |
Aggregate Balance
at Last FYE
($)
|
|
|
Mark S. Walchirk
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Donald J. Zurbay
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Eric R. Shirley
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
|
Les B. Korsh
|
| |
82,798
|
| |
-
|
| |
4,350
|
| |
-
|
| |
107,543
|
|
|
Kevin M. Pohlman
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
| |
-
|
|
(a)
|
Amounts reported in this column are also reported as salary in the Summary Compensation Table.
|
(b)
|
We do not make any contributions to The Executive Nonqualified Excess Plan.
|
(c)
|
Amounts reported in this column are not reported as compensation in the Summary Compensation Table.
|
|
|
| |
Mark S.
Walchirk
|
| |
Donald J.
Zurbay
|
| |
Eric R.
Shirley
|
| |
Les B.
Korsh
|
| |
Kevin M.
Pohlman
|
|
|
Involuntary Termination without Cause
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
Severance/Salary Continuation
|
| |
$3,156,592
|
| |
$1,381,469
|
| |
$1,078,866
|
| |
$922,017
|
| |
$874,487
|
|
|
Annual Cash Incentive
|
| |
1,663,150
|
| |
686,720
|
| |
407,450
|
| |
369,170
|
| |
356,990
|
|
|
Nonqualified Deferred Compensation Benefits
|
| |
-
|
| |
-
|
| |
-
|
| |
107,543
|
| |
-
|
|
|
Total:
|
| |
$4,819,742
|
| |
$2,068,189
|
| |
$1,486,316
|
| |
$1,398,729
|
| |
$1,231,477
|
|
|
Involuntary Termination without Cause following Change-in-Control, or Voluntary Termination for Good Reason following Change-in-Control
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
Severance/Salary Continuation
|
| |
$3,922,000
|
| |
$1,588,020
|
| |
$1,217,840
|
| |
$1,103,440
|
| |
$1,066,780
|
|
|
Annual Cash Incentive
|
| |
1,147,000
|
| |
473,620
|
| |
281,040
|
| |
254,640
|
| |
246,180
|
|
|
Gain on Accelerated Stock Options
|
| |
4,691,841
|
| |
1,885,255
|
| |
497,680
|
| |
653,366
|
| |
644,208
|
|
|
Accelerated Restricted Stock and Performance Units Awards
|
| |
9,001,926
|
| |
2,861,074
|
| |
2,020,703
|
| |
2,396,392
|
| |
2,219,723
|
|
|
Nonqualified Deferred Compensation Benefits
|
| |
-
|
| |
-
|
| |
-
|
| |
107,543
|
| |
-
|
|
|
Total:
|
| |
$18,762,767
|
| |
$6,807,969
|
| |
$4,017,263
|
| |
$4,515,380
|
| |
$4,176,891
|
|
|
Death or Disability
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
Gain on Accelerated Stock Options
|
| |
$4,691,841
|
| |
$1,885,255
|
| |
$497,680
|
| |
$653,366
|
| |
$644,208
|
|
|
Accelerated Restricted Stock and Performance Units Awards
|
| |
5,789,197
|
| |
1,870,391
|
| |
801,554
|
| |
801,554
|
| |
801,554
|
|
|
Nonqualified Deferred Compensation Benefits
|
| |
-
|
| |
-
|
| |
-
|
| |
107,543
|
| |
-
|
|
|
Total:
|
| |
$10,481,038
|
| |
$3,755,645
|
| |
$1,299,235
|
| |
$1,562,463
|
| |
$1,445,763
|
|
|
Retirement
|
| |
|
| |
|
| |
|
| |
|
| |
|
|
|
Accelerated Restricted Stock and Performance Unit Awards
|
| |
$-
|
| |
$-
|
| |
$-
|
| |
$-
|
| |
$796,448
|
|
|
Nonqualified Deferred Compensation Benefits
|
| |
-
|
| |
-
|
| |
-
|
| |
107,543
|
| |
-
|
|
|
Total:
|
| |
$-
|
| |
$-
|
| |
$-
|
| |
$107,543
|
| |
$796,448
|
|
■
|
In October 2017, we entered into an employment agreement with Mr. Walchirk. Under the terms of the agreement, Mr. Walchirk’s initial term of employment continued until November 20, 2020, at which time, the term renewed for 12-months. Unless notice to the contrary is provided, the term will renew for successive 12-month periods thereafter. The agreement provides for an annual base salary of $850,000 as well as participation in our other employee benefit plans and reimbursement for business expenses. Mr. Walchirk also is eligible to earn annual cash incentive compensation, which is payable if a threshold level of performance is achieved, pursuant to the MICP. The agreement provides that, if performance at target under the MICP is achieved, Mr. Walchirk’s annual cash incentive compensation would be $1,050,000 for any full year of employment. In addition, the agreement provides that Mr. Walchirk is eligible to receive annual long-term equity-based incentive compensation pursuant to the Amended and Restated 2015 Omnibus Incentive Plan, or any successor plan thereto, which awards consist of performance units, stock options, and restricted stock units, with an aggregate target value of $3,100,000. Mr. Walchirk’s base salary, annual cash incentive compensation, and annual long-term equity-based incentive compensation are reviewed on an annual basis and may be increased by the Board. Mr. Walchirk’s agreement also provided for an inducement award. On December 1, 2017, Mr. Walchirk was granted a restricted stock unit award outside the Amended and Restated 2015 Omnibus Incentive Plan covering a number of shares of our common stock with a value of $2,000,000 based on the per-share closing price of our common stock on the date of grant. Such award vested to the extent of 50% of the award on December 1, 2018 and the remaining 50% of the award on December 1, 2019. In addition, upon commencement of his employment, Mr. Walchirk received a lump-sum cash bonus of $100,000. If, during his term of employment, we terminate Mr. Walchirk without cause, Mr. Walchirk would be entitled to severance benefits, paid in a lump sum, including 24 months of base salary, cash incentive compensation equal to an average of the last three years of actual MICP incentives, proration of the current year MICP incentive based on actual performance, and 18 months of paid COBRA premiums. With a change in control, such severance benefits, also paid in a lump sum, would include 36 months of base salary, cash incentive compensation equal to his then current target MICP incentive, proration of the current year MICP incentive based on target performance, and 18 months of paid COBRA premiums. Mr. Walchirk also agreed to certain nondisclosure and non-disparagement provisions during his term of employment and any time thereafter, and certain non-competition and non-solicitation provisions during his term of employment and for three years thereafter.
|
■
|
In May 2018, we entered into an offer letter and an inducement, severance and change-in-control agreement with Mr. Zurbay. Pursuant to the offer letter, Mr. Zurbay’s employment, which commenced on June 29, 2018, is on an at-will basis. The offer letter provides for an annual base salary of $525,000 as well as participation in our other employee benefit plans and reimbursement for business expenses. Mr. Zurbay also is eligible to earn annual cash incentive compensation, which is payable if a threshold level of performance is achieved, pursuant to the MICP. If performance at target under the MICP is achieved, Mr. Zurbay’s annual cash incentive compensation would be 85% of his base salary. In addition, Mr. Zurbay is eligible to receive annual long-term equity-based incentive compensation pursuant to the Amended and Restated 2015 Omnibus Incentive Plan, or any successor plan thereto, which awards consist of restricted stock units, performance units, and stock options, with an aggregate target value of $1,000,000. Mr. Zurbay’s base salary, annual cash incentive compensation, and annual long-term equity-based incentive compensation are reviewed on an annual basis and may be adjusted by the Board. His agreement also provided for an inducement award consisting of a combination of stock options and restricted stock units. On June 29, 2018, Mr. Zurbay was granted a non-statutory stock option and a restricted stock unit award, both outside the Amended and Restated 2015 Omnibus Incentive Plan. The stock option has an approximate value of $750,000, a per-share exercise price equal to the per-share closing price of our common stock on the date of grant, and a term of ten years. Such award vested to the extent of one-third of the award on June 29, 2019, one-third of the award on June 29, 2020, and the remaining one-third of the award on June 29, 2021. The restricted stock unit award covered a number of shares of our common stock with a value of $700,000 based on the per-share closing price of our common stock on the date of grant. Such award vested to the extent of 50% of the award on June 29, 2019 and the remaining 50% of the award on June 29,
|
■
|
Between June 2018 and February 2019, we entered into restrictive covenants, severance and change-in-control agreements with Messrs. Shirley, Korsh and Pohlman. The agreements provide the executives with certain severance benefits. In connection with a termination of the executive’s employment without cause (as defined), the executive will receive in equal monthly installments over an 18-month period (A) cash in an amount equal to the sum of (i) one-and-one-half (1.5) times the executive’s then current base salary and (ii) the average of the executive’s annual cash incentive compensation paid under the MICP for each of the last three full fiscal years prior to the year in which the executive’s employment is terminated, (B) cash in an amount equal to the executive’s prorated annual cash incentive compensation under the MICP for the fiscal year in which termination occurs based on actual performance through the date of termination, and (C) if timely elected, up to 18 months of paid COBRA premiums. In the event that (x) the executive’s employment is terminated without cause (as defined) or (y) the executive resigns for good reason (as defined), in either case within two year immediately following a change in control (as defined), the executive will, in lieu of the above-described severance benefits, receive in a lump sum (A) cash in an amount equal to the sum of (i) two (2) times the executive’s then current base salary and (ii) the executive’s target annual cash incentive compensation under the MICP for the fiscal year in which the executive’s employment is terminated, (B) cash in an amount equal to the executive’s prorated annual cash incentive compensation under the MICP for the fiscal year in which termination occurs based on the executive’s target award through the date of termination, and (C) if timely elected, up to 18 months of paid COBRA premiums. In exchange for the severance benefits, the executive must sign and not revoke a waiver and release agreement. In consideration of the severance benefits and the below-described restricted stock unit award, each executive also has agreed to certain restrictive covenants including but not limited to post-employment non-compete and non-solicitation provisions for a restricted period (as defined). The restricted period is eighteen (18) months following the voluntary or involuntary termination of executive’s employment for whatever reason; provided, however, that it shall be twenty-four (24) months following (i) the involuntary termination of executive’s employment without cause (as defined) within two (2) years immediately following a change in control (as defined) or (ii) the executive’s resignation for good reason (as defined) within two (2) years immediately following a change in control (as defined). Each executive further agreed that we may terminate the executive’s right to the unvested restricted stock unit award, and may require reimbursement to our company by the executive of any incentive compensation previously paid or vested within the prior 12-month period, in certain circumstances. Upon entry into such agreements, Messrs. Shirley, Korsh and Pohlman each received a one-time restricted stock unit award with the following values under our Amended and Restated 2015 Omnibus Incentive Plan: Mr. Shirley ($600,000), Mr. Korsh ($1,500,000), and Mr. Pohlman ($1,250,000). For Mr. Shirley, such award will vest in full, assuming continued employment, on February 4, 2022. For Messrs. Korsh and Pohlman, such award vested to the extent of 25% of the award on June 11, 2019, 25% of the award on June 11, 2020, and the remaining 50% of the award on June 11, 2021.
|
■
|
Our Amended and Restated Equity Incentive Plan, which is no longer used for new grants, provides that awards issued under that plan are fully vested and all restrictions on the awards lapse in the event of a change-in-control, as defined in such plan.
|
■
|
Under our Amended and Restated 2015 Omnibus Incentive Plan, if the surviving or acquiring company in a change-in-control assumes our company’s outstanding incentive awards or provides for their equivalent substitutes, such plan provides for accelerated vesting of incentive awards following a change-in-control only upon the termination of the employee’s service, a material reduction in an employee’s base salary, a discontinuation of participation in certain long-term cash or equity benefits provided to comparable employees, a significant change in job responsibilities or the need to relocate, provided these events occur within two years of a change-in-control. The inducement awards issued outside our equity plans provide for the same change-in-control benefits.
|
■
|
The estimated median of the annual total compensation of all employees, except our President and Chief Executive Officer (our “non-CEO median employee”);
|
■
|
The annual total compensation of our President and Chief Executive Officer (our “CEO”); and
|
■
|
The estimated ratio of the annual total compensation of our CEO to the annual total compensation of our non-CEO median employee.
|
|
|
| |
Current
|
| |
After Approval of Amendment
to Omnibus Plan
|
| ||||||
|
Name
|
| |
Shares Reserved
for Issuance of
Outstanding
Awards (a)
|
| |
Shares Available
for Future Awards
|
| |
Shares Reserved
for Issuance of
Outstanding
Awards
|
| |
Shares Available
for Future Awards
|
|
|
2015 Omnibus Incentive Plan
|
| |
4,353,667
|
| |
1,734,733(b)
|
| |
4,353,667
|
| |
9,734,733
|
|
|
Amended and Restated Equity Incentive Plan (c)
|
| |
354,815
|
| |
-
|
| |
354,815
|
| |
-
|
|
|
Non-Shareholder Approved Awards (d)
|
| |
99,250
|
| |
-
|
| |
99,250
|
| |
-
|
|
|
Total
|
| |
4,807,732
|
| |
1,734,733
|
| |
4,807,732
|
| |
9,734,733
|
|
(a)
|
See below table for shares reserved for issuance of outstanding awards at July 16, 2021.
|
(b)
|
Computed based on the Omnibus Plan’s share counting provisions.
|
(c)
|
Following the 2015 approval of the Omnibus Plan, no new awards have been or may be made under the Amended and Restated Equity Incentive Plan.
|
(d)
|
Represents Donald J. Zurbay inducement award.
|
|
|
| |
Outstanding Awards
|
| |
|
| |
|
| |||
|
Name
|
| |
Options/SARs
|
| |
Full Value Awards
|
| |
Weighted Average
Exercise
Price of
Options/SARS
|
| |
Weighted Average
Term
to Expiration
|
|
|
2015 Omnibus Incentive Plan
|
| |
2,494,404
|
| |
1,859,263(a)
|
| |
$25.25
|
| |
8.06 years
|
|
|
Amended and Restated Equity Incentive Plan
|
| |
353,399
|
| |
1,416
|
| |
$53.64
|
| |
3.79 years
|
|
|
Non-Shareholder Approved Awards
|
| |
99,250
|
| |
-
|
| |
$22.67
|
| |
6.99 years
|
|
|
Total
|
| |
2,947,053
|
| |
1,860,679
|
| |
$28.57
|
| |
7.51 years
|
|
(a)
|
Includes 142,696 performance units granted in July 2019 which achieved a 142.5% payout based on performance and which remain subject to cliff vesting on July 1, 2022, 145,631 performance units granted in July 2020 the
|
|
|
| |
Fiscal
2021
|
| |
Fiscal
2020
|
| |
Fiscal
2019
|
|
|
Stock Options Granted
|
| |
540
|
| |
1,318
|
| |
621
|
|
|
Restricted Share Awards Granted
|
| |
33
|
| |
43
|
| |
37
|
|
|
Restricted Stock Units Granted
|
| |
513
|
| |
507
|
| |
773
|
|
|
Performance Units Earned
|
| |
0
|
| |
215
|
| |
124
|
|
|
Total
|
| |
1,086
|
| |
2,083
|
| |
1,555
|
|
|
Weighted Average Common Shares Outstanding
|
| |
95,599
|
| |
94,154
|
| |
92,755
|
|
|
Burn Rate
|
| |
1.14%
|
| |
2.21%
|
| |
1.68%
|
|
|
3-Year Average Burn Rate
|
| |
1.68%
|
| |
|
| |
|
|
■
|
No “evergreen” provision. The number of shares of common stock available for issuance under the Omnibus Plan is fixed and does not adjust based upon the number of outstanding shares of common stock.
|
■
|
Not excessively dilutive to shareholders. Subject to adjustment, the maximum number of shares of common stock authorized for issuance under the Omnibus Plan, if the proposed plan amendment is approved by our shareholders, will be 19,500,000.
|
■
|
Accounting for full value awards. The total number of shares of common stock available for issuance under the Omnibus Plan is reduced by 2.0 shares for each share issued pursuant to a “full value” award or potentially issuable pursuant to a “full value” award, which are awards other than stock options or stock appreciation rights (“SARs”) that are settled by the issuance of shares of common stock.
|
■
|
No “recycling” of shares from exercised stock options or SARs. Shares withheld to satisfy tax-withholding obligations on awards or to pay the exercise price of awards and any shares not issued or delivered because of a “net exercise” of a stock option or settlement of a SAR in shares of common stock do not become available for issuance as future award grants.
|
■
|
No stock option or SAR reloads. The Omnibus Plan does not authorize stock option or SAR reloads.
|
■
|
Stock option exercise prices and SAR grant prices are not lower than fair market value on grant date. The Omnibus Plan prohibits granting stock options with exercise prices and SARs with grant prices lower than the fair market value of a share of common stock on the grant date. The Omnibus Plan does allow for the subsequent adjustment of the exercise prices of outstanding awards in connection with certain corporate transactions, such as a recapitalization or stock split, as may be necessary in order to prevent dilution or enlargement of the rights of participants.
|
■
|
No re-pricing or exchange of “underwater” options or SARs without shareholder approval. The Omnibus Plan prohibits the re-pricing of outstanding stock options or SARs without shareholder approval, except in connection with certain corporate transactions, such as a recapitalization or stock split, as may be necessary in order to prevent dilution or enlargement of the rights of participants. The Omnibus Plan defines “re-pricing” broadly to include amendments or modifications to the terms of outstanding stock options or SARs to lower the exercise or grant price, canceling “underwater” stock options or SARs in exchange for cash, replacement awards having a lower exercise price or other awards, or repurchasing “underwater” stock options or SARs and granting new awards.
|
■
|
Stock options, SARs and unvested performance awards are not entitled to dividend equivalent rights. Stock option, SAR and unvested performance award holders have no rights as shareholders with respect to the shares underlying their awards until such awards are exercised or vested and shares are issued. As a result, stock options, SARs and unvested performance awards under the Omnibus Plan have no dividend equivalent rights associated with them.
|
■
|
Dividend equivalent rights on restricted stock units are subject to the same restrictions as the restricted stock units. Unless the compensation committee determines otherwise, restricted stock units granted under the Omnibus Plan carry a right to dividend equivalents. In all cases, dividend equivalents on restricted stock units are subject to the same conditions and restrictions as the restricted stock unit to which they relate.
|
■
|
Shareholder approval is required for material revisions to the plan. Consistent with NASDAQ listing rules, the Omnibus Plan requires shareholder approval of material revisions to the plan, including the proposed plan amendment. The Omnibus Plan also requires shareholder approval of certain additional revisions to the plan that would not otherwise require shareholder approval under NASDAQ listing rules.
|
■
|
Members of the committee administering the plan are non-employee, independent directors. The Omnibus Plan is administered by the compensation committee, or by a subcommittee thereof, or any other committee designated by the board in accordance with the Omnibus Plan. All members of any committee administering the Omnibus Plan are “non-employee directors” within the meaning of Rule 16b-3 under the Exchange Act and “independent” under the NASDAQ listing rules.
|
■
|
“Clawback” provisions. The Omnibus Plan contains “clawback” provisions. If the committee determines that a participant has taken any action that would constitute “cause” or an “adverse action,” as the Omnibus Plan defines such terms, while providing services to the company, or after termination of such services, all rights of the participant under the Omnibus Plan and any agreements evidencing an incentive award the participant then holds will terminate and be forfeited. In addition, the committee may require the participant to return to the company any shares received, any profits or any other economic value realized by the participant in connection with any awards or any shares issued upon the exercise or vesting of any awards. In addition, the Omnibus Plan incorporates the Sarbanes-Oxley Act of 2002 automatic forfeiture standard for certain participants in connection with material noncompliance, as a result of misconduct, resulting in an accounting restatement. In addition, all awards under the Omnibus Plan are subject to forfeiture or other penalties pursuant to any clawback or forfeiture policy of the company, as in effect from time to time, and such forfeiture and/or penalty conditions or provisions as determined by the committee and set forth in the applicable award agreement.
|
■
|
“Double-Trigger” vesting following change in control. If the surviving or acquiring company in a change in control assumes our company’s outstanding incentive awards or provides for their equivalent substitutes, the Omnibus Plan provides for accelerated vesting of incentive awards following a change in control only upon the
|
■
|
Minimum vesting and performance period requirements. No shares of common stock may be granted under the Omnibus Plan subject to: (a) SARs, restricted stock awards or restricted stock units granted to employees that vest solely based on continued service of the employees and that become exercisable more rapidly than ratably over a three-year period after the date of grant, except in connection with the death, disability or retirement of an employee or a change in control; (b) performance awards granted to employees with a performance period of less than one year; or (c) automatic grants awarded to non-employee directors with a vesting period of less than one year, subject to adjustment for such directors whose terms expire within 29 days of what would otherwise be the vesting date of the award, except in connection with the death or disability of a non-employee director or a change in control.
|
■
|
Select eligible participants to whom awards are granted;
|
■
|
Determine the types and amounts of awards to be granted and when;
|
■
|
Determine the provisions of such awards, including the applicable performance measures, if any, and the duration, restrictions and conditions of such incentive awards;
|
■
|
Subject to shareholder approval requirements for some amendments, determine whether and under what circumstances and terms to amend the Omnibus Plan or any outstanding incentive award agreement;
|
■
|
Interpret the Omnibus Plan and any instrument evidencing an incentive award under the Omnibus Plan and establish rules and regulations pertaining to its administration;
|
■
|
Determine fair market value in accordance with the Omnibus Plan;
|
■
|
Adopt subplans and adopt special provisions applicable to incentive awards regulated by the laws of jurisdictions other than the United States;
|
■
|
Authorize any person to execute on behalf of the company an incentive award agreement or other instrument required to effect a grant;
|
■
|
Determine whether incentive awards will be settled in shares of common stock, cash or in any combination thereof;
|
■
|
Determine whether an incentive award will be adjusted for dividend equivalents, provided, however, that no dividends or dividend equivalents will be paid out with respect to options, SARs and unvested performance awards;
|
■
|
Impose restrictions, conditions or limitations on resales and subsequent transfers; and
|
■
|
Make any other determination and take any other action that the committee deems necessary or desirable for administration of the Omnibus Plan.
|
■
|
500,000 shares subject to stock options and SARs;
|
■
|
500,000 shares subject to restricted stock awards and restricted stock units;
|
■
|
$5,000,000 or 500,000 shares of common stock in performance awards;
|
■
|
$5,000,000 in annual performance cash awards;
|
■
|
$5,000,000 in other cash-based awards; and
|
■
|
500,000 shares granted under other stock-based awards.
|
■
|
Sales and revenue measure elements, including gross revenue or sales, sales allowances, net revenue or net sales, invoiced revenue or sales, collected revenue or sales, revenues from new products, and bad debts;
|
■
|
Expense measurement elements, including direct material costs, direct labor costs, indirect labor costs, direct manufacturing costs, indirect manufacturing costs, cost of goods sold, sales, general and administrative expenses, operating expenses, non-cash expenses, tax expense, non-operating expenses, and total expenses;
|
■
|
Profitability and productivity measure elements, including gross margin, net operating income, EBITDA (earnings before interest, taxes, depreciation and amortization), EBIT (earnings before interest and taxes), net operating income after taxes (NOPAT), net income, net cash flow, and net cash flow from operations;
|
■
|
Asset utilization and effectiveness measure elements, including cash, excess cash, accounts receivable, inventory (WIP and/or finished goods), current assets, working capital, fixed assets, total assets, standard hours, plant utilization, purchase price variance, and manufacturing overhead variance;
|
■
|
Debt and equity measure elements, including accounts payable, current accrued liabilities, total current liabilities, total debt, debt principal payments, net current borrowings, total long-term debt, credit rating, retained earnings, total preferred equity, total common equity, and total equity;
|
■
|
Shareholder and return measure elements, including earnings per share (diluted and fully diluted), stock price, dividends, shares repurchased, total return to shareholders, debt coverage ratios, return on assets, return on equity, return on invested capital, and economic profit (for example, economic value added);
|
■
|
Customer and market measure elements, including dealer/channel size/scope, dealer/channel performance/effectiveness, order fill rate, customer satisfaction, customer service/care, brand awareness and perception, market share, warranty rates, product quality, and channel inventory; and
|
■
|
Organizational and employee measure elements, including headcount, employee performance, employee productivity, standard hours, employee engagement/satisfaction, employee turnover, and employee diversity.
|
■
|
All outstanding stock options (including non-employee director options) and SARs held by the participant will become immediately exercisable and will remain exercisable for a period of one year after such termination, but not later than the date the stock options or SARs expires;
|
■
|
All outstanding shares of restricted stock held by the participant will become fully vested;
|
■
|
All outstanding, but unpaid, restricted stock units, performance awards, other cash-based awards and other stock-based awards held by the participant will terminate and be forfeited. However, with respect to any incentive awards that vest based on the achievement of performance goals, if a participant’s employment or other service with the company or any subsidiary is terminated by death or disability prior to the end of the performance period of such award, but after the conclusion of a portion of the performance period (but in no event less than one year), the committee may, in its sole discretion, cause shares to be delivered or payment made with respect to the participant’s award, but only if otherwise earned for the entire performance period and only with respect to the portion of the applicable performance period completed at the date of such event, with proration based on full fiscal years only and no shares to be delivered for partial fiscal years; and
|
■
|
If the effective date of such termination is before the end of the time period to which an annual performance cash award relates, then any such annual performance cash award held by a participant will terminate and be forfeited, but if the effective date of such termination is on or after the end of the time period to which an annual performance cash award relates, then any such annual performance cash award held by a participant will be paid to the participant in accordance with the payment terms of such award.
|
■
|
All outstanding stock options (except non-employee director options) and SARs held by the participant will be unaffected by retirement, including vesting, exercisability and expiration requirements, except that any requirement to remain in continuous employment or service with the company shall be disregarded. Such options and SARs will not be exercisable later than the date the stock options or SARs expires;
|
■
|
All outstanding restricted stock awards held by the participant will be unaffected by retirement, including vesting requirements, except that any requirement to remain in continuous employment or service with the company shall be disregarded;
|
■
|
All outstanding, but unpaid, restricted stock units, performance awards, other cash-based awards and other stock-based awards held by the participant will be unaffected by such retirement, including vesting requirements, except that any requirement to remain in continuous employment or service with the company shall be disregarded. However, with respect to any incentive awards the vesting or payment amount of which is based on the achievement of performance goals, if a participant’s employment or other service with the company or any subsidiary, as the case may be, is terminated by reason of retirement prior to the end of the performance period of such incentive award, but after the conclusion of a portion of the performance period (but in no event less than one year), the committee shall cause shares to be delivered or payment made with respect to the participant’s award, but only if otherwise earned for the entire performance period and only with respect to the portion of the applicable performance period completed at the date of such event, with proration based on full fiscal years only and no shares to be delivered or payment amount determined for partial fiscal years; and
|
■
|
If the effective date of such retirement is before the end of the performance period to which an annual performance cash award relates, then any such annual performance cash award held by a participant will
|
■
|
All outstanding stock options (including non-employee director options) and SARs held by the participant that then are exercisable will remain exercisable for three months after the date of termination, but those that are not exercisable will terminate and be forfeited;
|
■
|
All stock options, SARs and outstanding shares of restricted stock held by the participant that then have not vested will terminate and be forfeited;
|
■
|
All outstanding, but unpaid, restricted stock units, performance awards, other cash-based awards and other stock-based awards held by the participant will terminate and be forfeited; and
|
■
|
All outstanding annual performance cash awards held by a participant will terminate and be forfeited.
|
■
|
If any “person” or “group” as those terms are used in Sections 13(d) and 14(d) of the Exchange Act or any successors thereto, is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act or any successor thereto), directly or indirectly, of securities of the company representing 50% or more of the combined voting power of the company’s then outstanding securities, provided, that the acquisition of additional securities by any person or group that owns 50% or more of the voting power prior to such acquisition of additional securities shall not be a Change in Control;
|
■
|
During any twelve-month period, individuals who at the beginning of such period constitute the board and any new directors whose election by the board or nomination for election by the company’s shareholders was approved by at least a majority of the directors then still in office who either were directors at the beginning of the period or whose election was previously so approved, cease for any reason to constitute a majority thereof;
|
■
|
The shareholders of the company approve a merger or consolidation of the company with any other corporation, other than a merger or consolidation (A) which would result in all or a portion of the voting securities of the company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than 50% of the combined voting power of the voting securities of the company or such surviving entity outstanding immediately after such merger or consolidation or (B) by which the corporate existence of the company is not affected and following which the company’s chief executive officer and directors retain their positions with the company (and constitute at least a majority of the board) and such merger or consolidation is consummated; or
|
■
|
The shareholders of the company approve an agreement for the sale or disposition by the company of all or substantially all the company’s assets and such sale or disposition is consummated.
|
■
|
All outstanding stock options and SARs will become immediately exercisable in full and will remain exercisable for the remainder of their terms, regardless of whether the participant to whom such stock options or SARs have been granted remains in employment or service with the company or any subsidiary;
|
■
|
All restrictions and vesting requirements applicable to any incentive award based solely on the continued service of the participant will terminate; and
|
■
|
All incentive awards the vesting or payment of which are based on performance goals will vest as though such performance goals were fully achieved at target and will become immediately payable.
|
■
|
All outstanding options and SARs will become immediately exercisable in full and will remain exercisable for the remainder of their terms, regardless of whether the participant to whom such options or SARs have been granted remains in employment or service with the company;
|
■
|
All restrictions and vesting requirements applicable to any incentive award based solely on the continued service of the participant will terminate; and
|
■
|
All incentive awards the vesting or payment of which are based on performance goals will vest as though such performance goals were fully achieved at target and will become immediately payable.
|
|
Name and Position
|
| |
Dollar Value(s)
|
| |
Number of Shares
|
|
|
Mark S. Walchirk
President and Chief Executive Officer of Patterson Companies, Inc.
|
| |
(a)
|
| |
(a)
|
|
|
Donald J. Zurbay
Chief Financial Officer and Treasurer of Patterson Companies, Inc.
|
| |
(a)
|
| |
(a)
|
|
|
Eric R. Shirley
Former President of Patterson Dental
|
| |
(a)
|
| |
(a)
|
|
|
Les B. Korsh
Vice President, General Counsel and Secretary of Patterson Companies, Inc.
|
| |
(a)
|
| |
(a)
|
|
|
Kevin M. Pohlman
President of Patterson Animal Health
|
| |
(a)
|
| |
(a)
|
|
|
Executive Group
|
| |
(a)
|
| |
(a)
|
|
|
Non-Executive Director Group
|
| |
$1,015,000
|
| |
(b)
|
|
|
Non-Executive Officer Employee Group
|
| |
(a)
|
| |
(a)
|
|
(a)
|
Awards granted under the Omnibus Plan to our executive officers and employees are discretionary and are not subject to set benefits or amounts, and we have not approved any awards that are conditioned on shareholder approval of this proposal. Accordingly, we cannot currently determine the benefits or number of shares subject to awards that may be granted in the future to our executive officers or employees under the Omnibus Plan.
|
(b)
|
Pursuant to our non-employee director compensation policy, each of our then current non-employee directors will receive an annual equity grant with a fair market value as of the date of grant of $145,000, comprised of restricted stock under the Omnibus Plan. The number of shares subject to such awards granted under the Omnibus Plan is determined on the basis of the fair market value of our common stock on the date of grant and, therefore, is not determinable at this time.
|
|
Plan Category
|
| |
Number of securities
to be issued upon
exercise of
outstanding options,
warrants and rights
(a)
|
| |
Weighted-
average exercise
price of
outstanding
options, warrants
and rights
(b)(1)
|
| |
Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column
(a))
(c)
|
|
|
Equity compensation plans approved by security holders
|
| |
2,886,209(2)
|
| |
$28.52
|
| |
6,103,377(3)
|
|
|
Equity compensation plans not approved by security holders
|
| |
99,250(4)
|
| |
$22.67
|
| |
-
|
|
|
Total
|
| |
2,985,459
|
| |
$28.31
|
| |
6,103,377
|
|
(1)
|
The weighted average exercise price does not take into account the shares issuable upon vesting of outstanding performance unit awards, which have no exercise price.
|
(2)
|
Represents (a) 360,926 shares of our common stock to be issued upon exercise of outstanding stock options under the Amended and Restated Equity Incentive Plan, (b) 2,236,956 shares of our common stock to be issued upon exercise of outstanding stock options, and (c) 288,327 performance units granted at target and unvested under the Amended and Restated 2015 Omnibus Incentive Plan.
|
(3)
|
Represents (a) 3,831,968 shares of our common stock available for issuance under the Amended and Restated 2015 Omnibus Incentive Plan, which replaced our Amended and Restated Equity Incentive Plan (under which no new awards may be granted), (b) 1,733,729 shares of our common stock available for issuance under the Employee Stock Purchase Plan, (c) 337,753 shares of our common stock available under the Capital Accumulation Plan, which includes 22,887 restricted awards unvested under such plan (under which no new participation is permitted), and (d) 199,927 shares of our common stock available under the 2014 Sharesave Plan.
|
(4)
|
Represents shares of our common stock to be issued upon exercise of outstanding stock options granted to Mr. Zurbay as an inducement to his employment.
|
|
|
| |
Fiscal Year Ended
April 24, 2021
|
| |
Fiscal Year Ended
April 25, 2020
|
|
|
Audit Fees
|
| |
$2,860,009
|
| |
$2,759,092
|
|
|
Audit-Related Fees
|
| |
178,000
|
| |
105,000
|
|
|
Tax Fees
|
| |
130,503
|
| |
202,352
|
|
|
All Other Fees
|
| |
4,020
|
| |
3,600
|
|
|
Total
|
| |
$3,172,533
|
| |
$3,070,044
|
|
|
| |
Fiscal year ended
|
||||||
(Dollars in thousands, except per share amounts)
|
| |
April 24, 2021
|
| |
April 25, 2020
|
| |
April 27, 2019
|
Net sales
|
| |
$5,912,066
|
| |
$5,490,011
|
| |
$5,574,523
|
Gross profit
|
| |
1,203,130
|
| |
1,197,410
|
| |
1,190,775
|
Operating income (loss)
|
| |
210,607
|
| |
(572,119)
|
| |
137,716
|
Net income (loss) attributable to Patterson Companies, Inc.
|
| |
155,981
|
| |
(588,446)
|
| |
83,628
|
Diluted earnings (loss) per share attributable to Patterson Companies, Inc.
|
| |
$1.61
|
| |
$(6.25)
|
| |
$0.89
|
Cash and cash equivalents
|
| |
$143,244
|
| |
$77,944
|
| |
$95,646
|
Working capital
|
| |
526,263
|
| |
467,867
|
| |
728,651
|
Total assets
|
| |
2,751,511
|
| |
2,715,350
|
| |
3,269,269
|
Total long-term debt
|
| |
487,545
|
| |
587,766
|
| |
725,341
|
Stockholders’ equity
|
| |
964,671
|
| |
836,444
|
| |
1,480,507
|
|
| |
Fiscal year ended
|
||||||
(Dollars in thousands, except per share amounts)
|
| |
April 24, 2021
|
| |
April 25, 2020
|
| |
April 27, 2019
|
Net income (loss) attributable to Patterson Companies, Inc. – GAAP
|
| |
$155,981
|
| |
$(588,446)
|
| |
$83,628
|
Deal amortization
|
| |
28,210
|
| |
28,208
|
| |
29,201
|
Integration and business restructuring expense
|
| |
817
|
| |
11,591
|
| |
–
|
Legal reserve costs
|
| |
–
|
| |
74,141
|
| |
20,740
|
Accelerated debt-related costs
|
| |
–
|
| |
7,457
|
| |
–
|
Discrete tax matters
|
| |
–
|
| |
–
|
| |
(2,686)
|
Investment gain
|
| |
–
|
| |
(25,983)
|
| |
–
|
Goodwill impairment
|
| |
–
|
| |
640,627
|
| |
–
|
Net income attributable to Patterson Companies, Inc. – non-GAAP
|
| |
$185,008
|
| |
$147,595
|
| |
$130,883
|
Diluted earnings (loss) per share attributable to Patterson Companies, Inc. – GAAP
|
| |
$1.61
|
| |
$(6.25)
|
| |
$0.89
|
Deal amortization
|
| |
0.29
|
| |
0.30
|
| |
0.31
|
Integration and business restructuring expense
|
| |
0.01
|
| |
0.12
|
| |
–
|
Legal reserve costs
|
| |
–
|
| |
0.78
|
| |
0.22
|
Accelerated debt-related costs
|
| |
–
|
| |
0.08
|
| |
–
|
Discrete tax matters
|
| |
–
|
| |
–
|
| |
(0.03)
|
Investment gain
|
| |
–
|
| |
(0.27)
|
| |
–
|
Goodwill impairment
|
| |
–
|
| |
6.74
|
| |
–
|
Diluted earnings per share attributable to Patterson Companies, Inc. – non-GAAP*
|
| |
$1.91
|
| |
$1.55
|
| |
$1.40
|
Operating income (loss) as a % of sales – GAAP
|
| |
3.6%
|
| |
-10.4%
|
| |
2.5%
|
Operating income (loss) as a % of sales – non-GAAP
|
| |
4.2%
|
| |
4.3%
|
| |
3.7%
|
*
|
May not sum due to rounding and difference in weighted average shares used to calculate diluted earnings (loss) per share.
|